Enantioselective Synthesis of *H*-Phosphinic Acids Bearing Natural Amino Acid Residues

Qiuli Yao and Chengye Yuan*

State Key Laboratory of Bio-organic and Natural Products Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 345 Lingling Road, Shanghai 200032, China

Supporting Information

ABSTRACT: The first systematic study on the asymmetric synthesis of *H*-phosphinic acids bearing natural protein amino acid residues was reported on the basis of the asymmetric addition of ethyl diethoxymethylphosphinate to *N*-tert-butane-sulfinyl imines. Good yields and moderate to high enantiose-



lectivities were obtained. Reliable methods were developed for the elucidation of the stereochemistry of these phosphinic acids and derivatives thereof. The transformation of the side chains of these analogues was studied. Methods for the conversion of the α -aminophosphinates to oligopetides were reported.

INTRODUCTION

As a phosphorus analogue of natural α -aminocarboxylic acid, α aminophosphonic acid is of great interest to chemists (Scheme 1). Many procedures have been developed for their preparation in both racemic and optically pure forms,¹ and their biological studies have revealed diverse activities.²

Scheme 1. α -Amino Acid and Its Phosphorus Analogues

| NH ₂ | | |
|----------------------|--------------------------------|--|
| R COOH | '\ '\`OH ОН | H H |
| α -amino acid | α -aminophosphonic acid | α -amino- <i>H</i> -phosphinic acid |


However, direct comparison of α -aminophosphonic acids with α -aminocarboxylic acids is not reasonable, since the former belongs to dibasic acids while the latter are monobasic acids in nature. From this structural point of view, α -amino-Hphosphinic acids are much closer to natural α -aminocarboxylic acids (Scheme 1). It is well documented that optically active α aminocarboxylic acids play an irreplaceable role in the biological metabolism. Consequently, it is reasonable to assume that better bioactivities can be expected for H-phosphinic analogues of α -amino acids than for corresponding phosphonic acids. Previous work by George et al. demonstrates that Nmethyl-N-amidinoaminomethylphosphinic acid is much more reactive as analogue of creatine in the creatine kinase reaction than the corresponding phosphonic acid or its monoester.^{3a} Similar effects were found for inhibitors of nitric oxide synthase (NOS).^{3b} In fact, derivatives of *H*-phosphinic acids have already demonstrated varieties of activities;⁴ also, the precursor of α aminophosphinates are excellent synthons for the preparation of various organophosphorus compounds.⁵

Unfortunately, probably because of the unique structure, it is difficult to synthesize chiral α -amino-*H*-phosphinic acids. Most of the available methods only lead to racemates.⁶ Thus, almost all current literature data recordings used racemic *H*-phosphinic

acids directly in their biological studies. As far as we know, only five α -amino-*H*-phosphinic acids have been described in the literature for their asymmetric syntheses.⁷ This might be due to three reasons. First, the high reactivity of P–H group usually makes the preparation of *H*-phosphinic acid difficult. Second, the stereochemistry for organophosphorus compounds is complex because of the delocalization of P=O bond due to d-p π bond. To be specific, reliable methods to elucidate the stereochemistry of *H*-phosphinic acids or phosphinates are lacked. Finally, additional functionalization of amino acids emphasizes the difficulty toward the asymmetric syntheses of *H*-phosphinic analogues of the natural α -amino acids. For these reasons, studies on the asymmetric synthesis and biological studies of this type of compound are challenging.

Recently, a convenient procedure for the preparation of optically active α -aminophosphinates by using N-tertbutanesulfinyl imines as chiral auxiliaries was described.⁸ Rb₂CO₃ was found to have suitable basicity in the asymmetric synthesis of phosphinates. Also, a procedure describing a one-pot transformation of protected P-H group into P-O or P-N group by bromine, which provides a convenient method to elucidate the absolute configuration and dr values of α -aminophosphinates, was developed.⁵ Herein, as a part of our systematic efforts in the study of H-phosphinic acids and their derivatives, we describe the first systematic stereoselective synthesis of Hphosphinic isosteres of α -amino acids (Scheme 2). Nucleophilic attack of ethyl diethoxymethylphosphinate on sulfinamide 1 bearing a side chain of a natural amino acid gave phosphinate 2, which was then subsequently converted to α -amino-Hphosphinate 3 or α -amino-*H*-phosphinic acid 4.

Received: April 15, 2013 **Published:** June 17, 2013 Scheme 2. Asymmetric Syntheses of α -Amino-H-phosphinic Acids



RESULTS AND DISCUSSION

Amino acids can be catalogued as follows: (i) nonfunctionalized amino acids (alanine, glycine, phenylalanine, valine, and leucine); (ii) amino acids with additional functionalities, including hydroxyl (serine, tyrosine, and threonine), sulfanyl (methionine and cysteine), amino (tryptophan, arginine, and proline), and amide linkage (asparagines, pyroglutamic acid, and glutamine); (iii) dicarboxylic acids (aspartic acid and glutamic acid); and (iv) amino acids containing two amino groups (lysine). In order to achieve the asymmetric synthesis of their phosphinic analogues, protection of additional functional group is necessary.

Consequently, (S)-sulfinamide 1 was first prepared by condensation of (S)-2-methylpropane-2-sulfinamide and corresponding aldehyde by $Ti(OPr^i)_4$ or $CuSO_4$,⁹ followed by a nucleophilic reaction with diethoxymethylphosphinate to give phosphinates 2 with Rb₂CO₃ as a base at room temperature (Table 1). For most of substrates 1 with side chains of natural amino acids, the reactions proceeded successfully and gave good to high yields. Except for 1k (entry 11), the product 2k underwent debromination and decomposed, so it was directly

Table 1. Preparation of Phosphinates 2^{a}

| Tuble II Trepulation of Thosphilates 2 | | | | |
|--|---------------------|--|--|------------------------|
| R | 0 \$ 1 | O HP-OEt CH(OEt) ₂ DCM, r.t. | ° ^t Bu [₩] ^S NH ► R ← P C 2 | ∠O `OEt H(OEt)2 |
| entry | 2 | R | time (h) | yield (%) ^b |
| 1 | 2a | Me | 30 | 84 |
| 2 | 2b | $PhtN(CH_2)_3$ | 17 | 92 |
| 3 | 2c | BnSCH ₂ | 10 | 91 |
| 4 | 2d | FmSCH ₂ | 40 | 90 |
| 5 | 2e | $MeOCO(CH_2)_2$ | 13 | 87 |
| 6 | 2f | (S)-sec-Bu | 36 | 80 |
| 7 | 2g | <i>i</i> -Bu | 24 | 90 |
| 8 | 2h | $PhtN(CH_2)_4$ | 36 | 94 |
| 9 | 2i | $MeS(CH_2)_2$ | 24 | 98 |
| 10 | 2j | Bn | 15 | 64 |
| 11 | 2k | $Br(CH_2)_3$ | 36 | - ^c |
| 12 | 21 | BnOCH ₂ | 72 | 50 |
| 13 | (–)-2l | $BnOCH_2^d$ | 17 | 88 |
| 14 | 2m | (R)-MeCH(OBn) | 17 | 92 |
| 15 | 2n | 3'-indolyl-CH ₂ | 36 | 96 |
| 16 | 20 | 4-MeOC ₆ H ₄ CH ₂ | 36 | 93 |
| 17 | 2p | <i>i</i> -Pr | 24 | 70 |

^{*a*}The reaction was carried out with **1** (5 mmol), ethyl diethoxymethylphosphinate (4 mmol) and Rb₂CO₃ (25 mmol) in 50 mL of DCM at room temperature. ^{*b*}Separated yield after column chromatography. ^{*c*}The product was unstable, and debromination was detected, so it was subjected to the next reaction without further purification. ^{*d*}(*R*)-Sulfinamide was used as substrate instead of (*S*)sulfinamide. subjected to the next reaction without further purification. (R)-Sulfinamide (-)-1l was used in this reaction as well (entry 13).

The removal of the protecting groups of phosphinate 2 was attempted. The conditions of 4 M HCl in the solvent of methanol at room temperature was found to be suitable to remove the *tert*-butylsulfinyl group to give phosphinate 3 with good to excellent yields (Table 2). This mild condition does

| Table 2. | Removal | of <i>tert</i> -Buty | lsulfinyl | Group of | 2 to |
|----------|---------------------|----------------------|-----------|----------|------|
| Phosphin | ates 3 ^a | | | | |

| | $\mathbf{R}^{O}_{Bu^{W^{W}}} \mathbf{S}_{NH}^{H}$ | 4 M HCI/MeOH ► R ¹ | NH ₂ → P → O → OEt → OEt CH(OEt) ₂ 3 |
|-------|---|----------------------------------|---|
| entry | 3 | \mathbb{R}^1 | yield (%) ^b |
| 1 | 3b | $PhtN(CH_2)_3$ | quant. |
| 2 | 3c | BnSCH ₂ | 90 |
| 3 | 3d | FmSCH ₂ | 83 |
| 4 | 3e | $EtOCO(CH_2)_2$ | 65 ^{<i>c</i>,<i>d</i>} |
| 5 | 3f | (S)-sec-Bu | 82 |
| 6 | 3g | <i>i</i> -Bu | 90 |
| 7 | 3h | $PhtN(CH_2)_4$ | 94 |
| 8 | 3i | $MeS(CH_2)_2$ | 99 |
| 9 | Зј | Bn | quant. |
| 10 | 3k | f | 80 ^e |
| 11 | 31 | BnOCH ₂ | quant. |
| 12 | (-)-31 | BnOCH ₂ | 92 |
| 13 | 3m | (R)-MeCH(OBn) | 96 |
| 14 | 3n | 3'-indolyl-CH ₂ | 93 |
| 15 | 3p | <i>i</i> -Pr | 98 |

^{*a*}The reaction was carried out with **2** (0.5 mmol) in 2.5 mL of 4 M HCl in MeOH at room temperature for 75 min. ^{*b*}Separated yield after column chromatography. ^{*c*}The reaction was carried out for 20 h with 1 M HCl in EtOH. ^{*d*}When the reaction was carried out for 33 h in 1 M HCl in EtOH, 16% **3e** and 29% product with conversion of the ester group to carboxylic group ($R^1 = CH_2CH_2COOH$) were given. ^{*c*}Separated yield for 2 steps from **1k**. ^{*f*}The structure of product **3k** is as follows:



not affect the phosphinate group at all, but side chains with a methyl ester group (2e, entry 4) would undergo transesterification to give an ethyl ester group when the reaction was performed with 1 M HCl in EtOH. When prolonging the reaction of 2e with 1 M HCl in EtOH, partial hydrolysis was detected as well (entry 4). Phosphinate 2k with a brominesubstituted side chain underwent cyclization to give phosphinate 3k under the acidic condition (entry 10).

Next, the removal of the protecting groups leading to final product 4 was investigated. Our initial study showed that when phosphinate 2 was directly treated with 4 M HCl by heating to reflux for 15 h, *H*-phosphinic acid 4 was obtained for specific substrates without any additional functional group (Table 3, entries 1, 4, 9, 10). However, this procedure often led to byproducts that may be caused by the sulfinamide group, especially for functionalized substrates. After an exploration of the reaction conditions, simply by the reaction of phosphinate 3 in 4 M aqueous HCl by heating to reflux for 1.5 h, the

Table 3. Preparation of Phosphinic Acids 4

| | 2 or 3 | 3 | | |
|-------|---------------|-----------|--|------------------------|
| entry | substrate | 4 | \mathbb{R}^1 | yield (%) |
| 1 | 2a | 4a | Me | 80 ^a |
| 2 | 3c | 4c | BnSCH ₂ | 95 ^b |
| 3 | 3f | 4f | (S)-sec-Bu | 97 ^b |
| 4 | 2g | 4g | <i>i</i> -Bu | 33 ^a |
| 5 | 3h | 4h | $PhtN(CH_2)_4$ | 49 ^b |
| 6 | 3i | 4i | $MeS(CH_2)_2$ | 84 ^b |
| 7 | 3j | 4j | Bn | 86 ^b |
| 8 | 3k | 4k | _ ^c | 63 ^b |
| 9 | 20 | 4o | 4-MeOC ₆ H ₄ CH ₂ | 60 ^{<i>a</i>} |
| 10 | 2p | 4p | <i>i</i> -Pr | 40 ^{<i>a</i>} |

^{*a*}Procedure A: **2** (0.2 mmol) in 4 M aqueous HCl (4 mL) was heated to reflux for 15 h and then treated with 20 mL of propylene oxide. ^{*b*}Procedure B: **3** (0.5 mmol) in 4 M aqueous HCl (2.5 mL) was heated to reflux for 1.5 h and then treated with 20 mL of propylene oxide. ^{*c*}The structure of product **4k** is as follows:




formation of byproducts was excluded (Table 3, entries 2, 3, 5–8).

Finally, the stereochemistry of these addition reactions was studied. ³¹P NMR analysis indicates that phosphinate **2** has two isomers as major products and additional two as minor products. However, it is difficult to separate these isomers by chromatography for most substrates except **2c** and **2m**, and the chirality at the phosphorus center increased the difficulty. Thus to discriminate the absolute configuration of each isomer is almost impossible. Nevertheless, *N-tert*-butanesulfinyl imines do not have asymmetric inductive effect to the phosphinates group,⁸ so just confirming the stereochemistry of the α -substituent is adequate and realizable. For phosphinate **2** and **3**, although its dr value can be detected by ³¹P NMR spectrum, we can not know the relative value between the isomer of (R_c) and (S_c), which actually reflects the enantioselectivities of these reactions.

Thus, methods to determine of the constituents of the α carbon were studied (Scheme 3). To achieve this, phosphinate 3 was transferred to the diethyl phosphonate 5 by our previously developed one-pot procedure (Scheme 3, eq 1),⁵

| Scheme 3. | Methods to | Determine | the | Ratio | of (| $R_c)/(S_c)$ |
|-----------|------------|-----------|-----|-------|------|--------------|



and then analysis of the NMR spectra of the Mosher's derivative **6** reflected its dr value. Also, oxidation and subsequent transformation of phosphinic acid **4** give phosphonate 7 (Scheme 3, eq 2). Further determination of the er value of compound **4** can be achieved by analysis of the HPLC spectrum of compound **7**. Direct conversion of **4** to its Mosher's derivative **8** provides another procedure to determine the er value of **4** (Scheme 3, eq 3) in the condition that diastereoisomers of **8** are distinguishable in their NMR or HPLC spectra. By the above procedures, the relative ratio of (R_c) and (S_c) isomers of **3** and **4** was determined (Table 4).

| Table 4. The Rati | o of $(R_c)/($ | (S_c) for 3 or 4 |
|-------------------|----------------|--------------------|
|-------------------|----------------|--------------------|

| 3 | Procedure A | 6 |
|---|-------------|---|
| | | |

4 Procedure B 7

4 Procedure C 8


| | | + | | |
|-------|-----------|----------------------------|------------------------|-------------------------|
| entry | substrate | \mathbb{R}^1 | procedure ^a | ratio of $(R_c)/(S_c)$ |
| 1 | 4a | Me | В | 90:10 |
| 2 | 3b | $PhtN(CH_2)_3$ | Α | 90:10 |
| 3 | 3c | BnSCH ₂ | _ | single isomer separated |
| 4 | 3e | $EtOCO(CH_2)_2$ | А | 88:12 |
| 5 | 4f | (S)-sec-Bu | В | 97:3 |
| 6 | 4g | <i>i</i> -Bu | В | 88:12 |
| 7 | 4h | $PhtN(CH_2)_4$ | В | 89:11 |
| 8 | 4i | $MeS(CH_2)_2$ | С | 81:19 |
| 9 | 4j | Bn | В | 90:10 |
| 10 | 4k | - | В | 79:21 |
| 11 | 31 | BnOCH ₂ | А | 66:34 |
| 12 | (–)-3l | BnOCH ₂ | А | 69:31 |
| 13 | 3m | (R)-MeCH(OBn) | _ | single isomer separated |
| 14 | 3n | 3'-indolyl-CH ₂ | A^b | 95:5 |
| 15 | 4o | $4-MeOC_6H_4CH_2$ | В | 88:12 |
| 16 | 3p | <i>i</i> -Pr | Α | >95:5 |
| 17 | 4p | <i>i</i> -Pr | В | >99:1 |
| | | | | |

^{*a*}Procedure A: Ratio of $(R_c)/(S_c)$ was measured by NMR spectra of 6. Procedure B: Ratio of $(R_c)/(S_c)$ was determined by chiral HPLC analysis of 7. Procedure C: Ratio of $(R_c)/(S_c)$ was estimated by NMR spectra and HPLC spectrum of 8. ^{*b*}The indolyl group of 3n was dibrominated.

For sterically hindered substrates such as 4f (entry 5), 3n (entry 14), and 3p (entry 16, 17), excellent enantioselectivities were obtained, while less sterically hindered substrates (entry 1, 2, 4, 6–9, 15) provide good enantioselectivities. For 3l or (-)-3l with a side chain of benzyloxy methyl group, relatively low dr values resulted for both (S) and (R)-sulfinamide (entry 11, 12), indicating that the asymmetric inductive effect of these two isomers was similar. Similar ratios were measured by both procedure A (entry 16) and procedure B (entry 17), indicating that both these two methods are liable to elucidate the enantioseletivity of these reactions. The major isomer of 2c and 2m were separated in yields of 48 and 45%, respectively. Subsequently they were subjected to the reaction providing single isomer of 3c and 3m, respectively (entry 3, 13).

Next, the absolute configuration of the α -carbon atom was investigated by analyses of ¹H NMR spectra of Mosher's derivatives **6p**, which are single isomers, and it can be confirmed to be *R* (Table 5, Figure 1). Similar analyses of the derivatives of the Mosher's derivatives of the major isomer of **3m** go to the same conclusion.¹⁰ These results indicate that

Table 5. ¹H NMR Data of (S) and (R)-Mosher's Derivative 6p



| | $\delta_{1~(ext{CH}_3)_2}$ | $\delta_{2~{ m CH}}$ | $\delta_{ m 3\ CH}$ | $\delta_{4~{ m CH}_2*2}$ | $\delta_{5~{ m CH}_3*2}$ |
|---------------------------|-----------------------------|----------------------|---------------------|--------------------------|--------------------------|
| (R)-MTPA | 1.06 | 2.31 | 4.35 | 4.06 | 1.26 |
| (S)-MTPA | 0.93 | 2.25 | 4.35 | 4.14 | 1.33 |
| $\Delta \delta_{(S)-(R)}$ | -0.13 | -0.06 | 0 | 0.08 | 0.07 |
| $\Delta \delta_{(S)-(R)}$ | <0 | <0 | 0 | >0 | >0 |





Figure 1. Absolute configuration of 3p elucidated by Mosher's method.

the major isomer of **3** or **4** has the absolute configuration of *R* at the α -carbon atom.

Further conversion of the side chains of the compounds 3 was studied. Transformation of the ester group of 2e to amide group proceeded successfully in aqueous ammonia or BnNH₂ leading to 2q (Scheme 4, eq 4) or 2r (Scheme 4, eq 5),

Scheme 4. Transformation of Ester Group to Amide Group




$$2e \xrightarrow{BnNH_2, MeOH}_{r.t., yield 95\%} BnHN \xrightarrow{VH}_{Durives} NH \underbrace{2.3 M HCl/EtOAc}_{proded 39\%} BnHN \xrightarrow{VH_2}_{proded 39\%} CH(OEt)_2 (5)$$

respectively. Quite interestingly, when 2q was reacted with 4 M HCl in MeOH, intramolecular amidation took place and 3q was obtained in 66% yield. As we know, 3q is the intermediate toward the analogue of L-pyroglutamic acid. Also, 3q can be transferred to 3k, the intermediate of the analogue of L-proline. **3e** was converted to 3q by aqueous ammonia in quantitative yield too (Scheme 4, eq 6), so the intramolecular amidation

could take place under either acidic or basic conditions. Trying to remove the benzyl group of 3l, (-)-3l or 3m by Pd/C and hydrogen failed. However, under the conditions of Pd $(OH)_2/C$ and hydrogen, this group could be deprotected successfully to give corresponding alcohols (Scheme 5).


The β -hydroxyl group of phosphinate 3s or (-)-3s can be transferred into amide group or carboxylic group via a cyano

Scheme 5. Removal of Benzyl Group



intermediate 9a or (-)-9a (Scheme 6). First, 3s or (-)-3s was converted to 9a or (-)-9a. Then in hydrogen peroxide, 9a was

Scheme 6. Transformation of the Analogues of Serine to Asparagine and Aspartic Acid



converted to 9b, after removal of the Boc group of which, 3u, which is the intermediate of asparagine, was obtained in quantitative yield. The cyano group of (-)-9a was transferred to carboxylic group when refluxed in 4 M HCl giving the analogue of D-aspartic acid (-)-4v.

As demonstrated in our previous work,⁵ the P–H group of phosphinate 3 can be transferred to different groups such as P–O or P–N group. Also, condensation of phosphinate 3 with *N*-protected amino acids or dipeptides (Table 6) leads to phosphorus-oligopeptide 10 in moderate to quantitative yields by EDCI and HOBt.

These phosphorus-oligopeptides could be functioned as peptidomimetics for natural peptides. Previous studies have revealed their diverse bioactivity.⁴ Initiate study on the bioactivity of these compounds indicates that compound **10a** may have inhibitive effect toward cell division cycle 25 homologue B (*Schizosaccharomyces pombe*) (CDC25B), which has oncogenic properties.¹¹

CONCLUSIONS

The first systematic enantioselective preparation of Hphosphinic analogues of α -amino acids has been studied on the basis of the asymmetric addition of phosphinates to *N*-tertbutanesulfinyl imines. Good yields and moderate to excellent enantioselectivities have been obtained for 17 substrates with side chains of natural α -amino acids. The transformation of the

Table 6. Preparation of Oligopeptide 10 from Phosphinate 3^{a}

| | NI ₹ | Carboxyli | ic component DCI, DCM R ¹ | NHCOR P ^O CH(OEt 10 | :)2 |
|-------|---------|------------------|---|--|----------------|
| entry | 3 | \mathbb{R}^1 | carboxylic component | 10 | yield $(\%)^b$ |
| 1 | 3f | (S)-sec-Bu | Boc-Phe-OH | 10a | 79 |
| 2 | 3f | (S)-sec-Bu | Boc-Val-OH | 10b | quant. |
| 3 | 3j | Bn | Boc-Val-OH | 10c | 81 |
| 4 | 3g | <i>i</i> -Bu | Fmoc-Ala-OH | 10d | quant. |
| 5 | 3h | $PhtN(CH_2)_4$ | Cbz-Gly-OH | 10e | 93 |
| 6 | 3f | (S)-sec-Bu | Boc-Phe-Val-OH | 10f | 76 |
| 7 | 3g | <i>i</i> -Bu | Boc-Phe-Val-OH | 10g | 49 |
| 8 | 3j | Bn | Boc-Phe-Val-OH | 10h | 35 |
| 9 | 3p | <i>i</i> -Pr | Boc-Phe-Val-OH | 10i | 67 |
| 10 | 3p | <i>i</i> -Pr | Boc-Phe-OH | 10j | 98 |
| 11 | 3g | <i>i</i> -Bu | Boc-Phe-OH | 10k | 82 |
| 12 | 3r | $BnNHCO(CH_2)_2$ | Boc-Phe-OH | 101 | 44 |
| 13 | 3f | (S)-sec-Bu | Boc-Trp-OH | 10m | 78 |

^{*a*}The reaction was carried out with 0.55 mmol carboxylic compound, 0.6 mmol HOBt, 0.6 mmol EDCI and 0.5 mmol 3 in 5.5 mL of DCM at 0 $^{\circ}$ C and then room temperature. ^{*b*}Separated yield after column chromatography.

analogue of glutamic acid to glutamine and pyroglutamic acid, and transformation of the analogue of serine to asparagine and aspartic acid analogues are studied as well. This study provides guidelines for the investigation of the stereochemistry of organophosphorus compounds in future studies. Furthermore, phosphorus-containing peptides are prepared from α -aminophosphinates, and their potent biological activities as peptidomimetics could be expected in the future.

EXPERIMENTAL SECTION

General Methods. Reactions were performed under nitrogen unless otherwise stated. Materials were obtained from commercial suppliers and used without further purification unless otherwise indicated. Preparative thin-layer chromatography (TLC) was performed with plates precoated with silica gel G.F. Flash chromatography was performed using silica gel (300–400 mesh). HRMS were detected by FT-ICR MS.

Procedure for Preparation of 1.⁷ Procedure A: To a solution of (S)-2-methylpropane-2-sulfinamide (1820 mg, 15 mmol) in 30 mL of DCM, CuSO₄ (4849 mg, 30 mmol) and 20 mmol aldehyde were added at room temperature. After completion of the reaction monitored by TLC, the solution was filtered by Celite, washed by EtOAc, and then purified by silica gel column chromatography with petroleum ether/ethyl acetate (1:15 to 1:7) to give 1a, 1e, 1j or 1p. Data for compounds 1a,¹² 1j,^{9b} and 1p,^{9b} were in accordance with reported data. Compounds 1 are mainly in *E* form, but at times *Z* form can be detected by NMR. Most of them were unstable at room temperature, so they should be used as soon as they were purified.

Procedure B: To (*S*)-2-methylpropane-2-sulfinamide (623 mg, 5 mmol), Ti(OPr['])₄ (2840 mg, 10 mmol), 6 mmol aldehyde and 1.5 mL of THF were added at room temperature. After completion of the reaction monitored by TLC, the solution was quenched by 1 mL of water with stirring, and 100 mL of ethyl acetate was added and then filtered by Celite. The solid was washed by 30 mL of ethyl acetate. The combined ethyl acetate phases were dried over anhydrous Mg₂SO₄ and then purified by silica gel column chromatography with petroleum ether/ethyl acetate (1:15 to 1:7) to give 1b, 1c, 1d, 1f, 1g, 1h, 1i, 1k, 1l, (-)-1l, 1m, 1n, and 1o. Data for compounds $1g^{13}$ and (-)- 11^{14} were in accordance with reported data.

Compound 1b. Yield 86%, 1.38 g; white solid: mp 77 °C; $[\alpha]_D^{21}$ 158.6 (*c* 1.0, CHCl₃); IR (film) 2957, 2925, 1712, 1396, 1083, 720 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 8.09 (t, *J* = 3.6 Hz, 1H), 7.85 (dd, *J*₁ = 2.8 Hz, *J*₂ = 5.2 Hz, 2H), 7.72 (dd, *J*₁ = 3.2 Hz, *J*₂ = 5.2 Hz, 2H), 3.79 (t, *J* = 6.8 Hz, 2H), 2.60 (m, 2H), 2.05 (m, 2H), 1.19 (s, 9H); ¹³C NMR (CDCl₃, 100 MHz) δ 168.4, 167.9, 134.0, 132.1, 123.3, 56.7, 37.4, 33.5, 24.2, 22.3; MS (ESI) *m/z* (%) 343.1 [M + Na]⁺; HRMS (ESI) Calcd for C₁₆H₂₀N₂O₃SNa 343.1087, found 343.1101. Elemental analysis (%) calcd for C₁₆H₂₀N₂O₃S: C 59.98, H 6.29, N 8.74. Found: C 59.96, H 6.36, N 8.54.

Compound 1c. Yield 63%, 0.85 g; colorless oil: $[\alpha]_D^{22}$ 265.7 (c 1.0, CHCl₃); IR (film) 3028, 2977, 2959, 2924, 1611, 1454, 1087, 701 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.98 (t, *J* = 5.2 Hz, 1H), 7.35–7.24 (m, 5H), 3.70 (s, 2H), 3.35 (t, *J* = 5.6 Hz, 2H), 1.23 (s, 9H); ¹³C NMR (CDCl₃, 100 MHz) δ 164.1, 137.3, 129.2, 128.7, 127.4, 57.0, 35.6, 34.4, 22.4; MS (ESI) *m*/*z* (%) 270.1 [M + H]⁺; HRMS (ESI) Calcd for C₁₃H₁₉NNaOS₂ 292.0800, found 292.0801.

Compound 1d. Yield 71%, 1.27 g; yellow solid: mp 72–73 °C; $[\alpha]_D^{22}$ 191.4 (*c* 1.0, CHCl₃); IR (film) 3064, 2959, 2923, 2863, 1610, 1450, 1086, 743 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.96 (t, *J* = 5.6 Hz, 1H), 7.74 (d, *J* = 7.6 Hz, 2H), 7.66 (d, *J* = 7.6 Hz, 1H), 7.60 (d, *J* = 7.6 Hz, 1H), 7.38 (t, *J* = 7.2 Hz, 2H), 7.30 (t, *J* = 7.6 Hz, 2H), 4.11 (t, *J* = 6.4 Hz, 1H), 3.48–3.34 (m, 1H), 3.39–3.34 (m, 1H), 3.13–2.98 (m, 1H), 3.03–2.98 (m, 1H), 1.20 (s, 9H); ¹³C NMR (CDCl₃, 100 MHz) δ 164.0, 145.6, 141.1, 127.7, 127.1, 124.8, 120.0, 57.0, 46.6, 36.1, 35.6, 22.4; MS (ESI) *m*/*z* (%) 358.1 [M + H]⁺. Elemental analysis (%) calcd for C₂₀H₂₃NOS₂: C 67.19, H 6.48, N 3.92. Found: C 66.79, H 6.55, N 3.73.

Compound **1e**. Yield 44%, 1.44 g; colorless oil: $E/Z \approx 5.2:1$; $[\alpha]_D^{26}$ 187.8 (*c* 1.1, CHCl₃); IR (film) 2954, 2870, 1739, 1625, 1475, 1438, 1365, 1213, 1169, 1085, 998, 583 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 8.13 (t, *J* = 2.8 Hz, 1H), 3.68 (s, 3H), 2.84 (m, 2H), 2.68 (m, 2H), 1.17 (s, 9H); ¹³C NMR (CDCl₃, 100 MHz) δ 172.7, 167.2, 56.8, 51.8, 31.0, 29.1, 22.2; MS (ESI) *m*/*z* (%) 220.1 [M + H]⁺; HRMS (EI) Calcd for C₉H₁₇NO₃S 219.0929, found 219.0933.

Compound **1f.** Yield 38%, 0.36 g; colorless oil: $[\alpha]_D^{27}$ 208.7 (*c* 1.0, CHCl₃); IR (film) 2964, 2929, 2875, 1620, 1458, 1363, 1087, 1016, 725, 586 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 7.97 (d, *J* = 5.1 Hz, 1H), 2.55 (m, 1H), 1.66 (m, 1H), 1.50 (m, 1H), 1.20 (s, 9H), 1.14 (d, *J* = 6.9 Hz, 3H), 0.95 (t, *J* = 7.8 Hz, 3H); ¹³C NMR (CDCl₃, 100 MHz) δ 173.3, 56.4, 41.6, 26.7, 22.3, 16.4, 11.5; MS (ESI) *m/z* (%) 190.1 [M + H]⁺; HRMS (ESI) Calcd for C₉H₂₀NOS 190.1266, found 190.1265.

Compound 1h. Yield 72%, 1.21 g; colorless oil: $[α]_D^{28}$ 154.5 (*c* 1.4, CHCl₃); IR (film) 3466, 2947, 1771, 1712, 1622, 1467, 1397, 1364, 1081, 1047, 721 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 8.06 (t, *J* = 4.8 Hz, 1H), 7.84 (dd, *J*₁ = 3.2 Hz, *J*₂ = 5.6 Hz, 2H), 7.72 (dd, *J*₁ = 3.2 Hz, *J*₂ = 5.6 Hz, 2H), 3.73 (t, *J* = 6.8 Hz, 2H), 2.59 (m, 2H), 1.77 (m, 2H), 1.71 (m, 2H), 1.18 (s, 9H); ¹³C NMR (CDCl₃, 100 MHz) δ 168.8, 168.3, 134.0, 132.1, 123.2, 56.5, 37.5, 35.4, 28.1, 22.6, 22.3; MS (ESI) *m/z* (%) 335.2 [M + H]⁺; HRMS (ESI) Calcd for C₁₇H₂₂N₂O₃SNa 357.1243, found 357.1255.

Compound 1i. Yield 80%, 0.83 g; colorless oil: $[\alpha]_D^{25}$ 69.4 (*c* 2.0, CHCl₃); IR (film) 2960, 2917, 2867, 1623, 1428, 1363, 1184, 1087, 1018, 687, 582 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 8.09 (t, *J* = 2.8 Hz, 1H), 2.84–2.80 (m, 4H), 2.13 (s, 3H), 1.21 (s, 9H); ¹³C NMR (CDCl₃, 100 MHz) δ 167.4, 56.7, 35.6, 29.5, 22.3, 15.5; MS (ESI) *m/z* (%) 208.1 [M + H]⁺; HRMS (ESI) Calcd for C₈H₁₇NOS₂Na 230.0644, found 230.0646.

Compound 1k. Yield 70%, 0.89 g; colorless oil: $[α]_D^{28}$ 187.3 (*c* 1.0, CHCl₃); IR (film) 3480, 2964, 2926, 1629, 1455, 1363, 1247, 1081, 583 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 8.11 (t, *J* = 4.0 Hz, 1H), 3.50 (m, 2H), 2.72 (m, 2H), 2.23 (m, 2H), 1.20 (s, 9H); ¹³C NMR (CDCl₃, 100 MHz) δ 167.8, 56.7, 34.4, 32.6, 28.1, 22.4; MS (ESI) *m/z* (%) 254.0 [M + H]⁺; HRMS (EI) Calcd for C₈H₁₆NOSBr 253.0136, found 253.0137.

Compound 1I. Yield 56%, 0.71 g; colorless oil: $[\alpha]_D^{23}$ 220.6 (*c* 0.8, CHCl₃); IR (film) 3063, 3031, 2960, 2926, 2866, 1632, 1274, 1455, 1363, 1085, 739, 699 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 8.13 (t, *J* = 3.2 Hz, 1H), 7.37–7.31 (m, SH), 4.64 (s, 2H), 4.41 (t, *J* = 2.4 Hz,

2H), 1.22 (s, 9H); ¹³C NMR (CDCl₃, 100 MHz) δ 166.8, 137.2, 128.6, 128.1, 127.9, 73.3, 71.3, 57.0, 22.4; MS (ESI) *m/z* (%) 254.1 [M + H]⁺; HRMS (EI) Calcd for C₁₃H₁₉NO₂S 253.1137, found 253.1140.

Compound 1m. Yield 79%, 1.06 g; colorless oil: $[\alpha]_D^{27}$ 327.4 (*c* 1.0, CHCl₃); IR (film) 3031, 2929, 2868, 1624, 1455, 1365, 1088, 699 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 8.06 (d, *J* = 4.4 Hz, 1H), 7.36–7.26 (m, 5H), 4.65 (d, *J* = 11.6 Hz, 1H), 4.53 (d, *J* = 11.6 Hz, 1H), 4.34 (m, 1H), 1.39 (d, *J* = 6.8 Hz, 3H), 1.21 (s, 9H); ¹³C NMR (CDCl₃, 100 MHz) δ 170.6, 137.6, 128.5, 127.9, 127.8, 76.3, 71.7, 57.0, 22.4, 18.7; MS (ESI) *m*/*z* (%) 268.1 [M + H]⁺; HRMS (ESI) Calcd for C₁₄H₂₁NO₂SNa 290.1185, found 290.1197.

Compound **1n**. Yield 48%, 0.63 g; yellow oil: $[\alpha]_D^{26}$ 205.3 (*c* 1.0, CHCl₃); IR (film) 3290, 3059, 2960, 1620, 1457, 1064, 742 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 8.32 (br, 1H), 8.16 (t, *J* = 5.2 Hz, 1H), 7.58 (d, *J* = 8.0 Hz, 1H), 7.36 (d, *J* = 8.0 Hz, 1H), 7.20 (dt, *J*₁ = 1.2 Hz, *J*₂ = 8.0 Hz, 1H), 7.12 (dt, *J*₁ = 0.8 Hz, *J*₂ = 8.0 Hz, 1H), 7.05 (d, *J* = 2.0 Hz, 1H), 3.95 (d, *J* = 5.2 Hz, 2H), 1.19 (s, 9H); ¹³C NMR (CDCl₃, 100 MHz) δ 167.7, 136.3, 127.2, 122.7, 122.4, 119.7, 118.7, 111.3, 109.0, 56.8, 32.5, 22.4; MS (ESI) *m/z* (%) 263.0 [M + H]⁺; HRMS (ESI) Calcd for C₁₄H₁₉N₂OS 263.1213, found 263.1220.

Compound **10.** Yield 66%, 0.84 g; yellow oil: $[\alpha]_D^{24}$ 267.0 (*c* 2.0, CHCl₃); IR (film) 2958, 2835, 1620, 1512, 1248, 1177, 1086, 831, 667 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 8.10 (t, *J* = 4.8 Hz, 1H), 7.14 (d, *J* = 8.4 Hz, 2H), 6.86 (d, *J* = 8.8 Hz, 2H), 3.79 (s, 3H), 3.76 (m, 2H), 1.18 (s, 9H); ¹³C NMR (CDCl₃, 100 MHz) δ 167.7, 158.7, 130.3, 126.7, 114.3, 56.8, 55.3, 41.8, 22.4; MS (ESI) *m*/*z* (%) 254.1 [M + H]⁺; HRMS (ESI) Calcd for C₁₃H₂₀NO₂S 254.1209, found 254.1209.

Procedure for Preparation of 2. To Rb_2CO_3 (5770 mg, 25 mmol), ethyl diethoxymethylphosphinate (3920 mg, 20 mmol), and 50 mL of DCM were added at room temperature. After 15 min, compound 1 (5 mmol) was added to the solution. After completion of the reaction monitored by TLC, the reaction was quenched by 30 mL of water and then extracted with ethyl acetate (50 mL × 3) and washed with 30 mL of brine. The combined organic phases were dried over anhydrous Na₂SO₄ and then purified by silica gel column chromatography with petroleum ether/ethyl acetate (2:3 to 1:5) to give 2.

Compound **2a.** Yield 84%, 1.44 g; colorless oil: $[\alpha]_D^{25}$ 64.1 (*c* 2.0, CHCl₃); IR (film) 3465, 3184, 2978, 2931, 1740, 1653, 1476, 1391, 1365, 1296, 1216, 1061, 959, 557 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 4.97 (m, 1H), 4.27 (m, 2H), 4.12 (m, 1H), 3.93–3.73 (m, 5H), 1.50–1.41 (m, 3H), 1.39–1.34 (m, 3H), 1.29–1.27 (m, 6H), 1.23 (s, 9H); ¹³C NMR (CDCl₃, 100 MHz) δ for the major isomer, 100.3 (d, *J* = 140.3 Hz), 66.1 (d, *J* = 9.3 Hz), 65.4 (d, *J* = 8.8 Hz), 62.3 (d, *J* = 7.4 Hz), 55.8 (d, *J* = 0.9 Hz), 46.8 (d, *J* = 95.4 Hz), 22.3 (s), 16.5 (d, *J* = 5.1 Hz), 15.1 (d, *J* = 7.5 Hz), 14.5 (d, *J* = 0.9 Hz); ³¹P NMR (CDCl₃, 162 MHz) δ 39.11, 38.89, 38.72, 38.24; MS (ESI) *m*/*z* (%) 344.2 [M + H]⁺, 366.3 [M + Na]⁺; HRMS (MALDI) Calcd for C₁₃H₃₁NO₅PS 344.1655, found 344.1648.

Compound **2b**. Yield 92%, 1.46 g; colorless oil: $[\alpha]_D^{26}$ 33.6 (*c* 1.0, CHCl₃); IR (film) 3471, 3198, 2977, 1713, 1396, 1060, 722 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.83 (m, 2H), 7.72 (m, 2H), 5.07 (m, 1H), 4.26 (m, 2H), 3.95–3.75 (m, 4H), 3.70 (m, 4H), 2.0 (m, 2H), 1.83–1.64 (m, 2H), 1.26–1.22 (m, 18H); ¹³C NMR (CDCl₃, 100 MHz) δ for the major isomer, 168.3 (s), 133.9 (s), 132.1 (s), 123.2 (s), 99.6 (d, *J* = 139.3 Hz), 66.1 (d, *J* = 10.2 Hz) and 65.2 (d, *J* = 9.5 Hz), 62.7 (d, *J* = 6.6 Hz), 56.8 (s), 52.0 (d, *J* = 89.0 Hz), 37.6 (s), 27.2 (s), 25.0 (d, *J* = 9.5 Hz), 22.7 (s), 16.7 (d, *J* = 5.1 Hz), 15.3 (m); ³¹P NMR (CDCl₃, 121 MHz) δ 40.11, 39.59, 39.07, 38.70; MS (ESI) *m/z* (%) 517.4 [M + H]⁺; HRMS (ESI) Calcd for C₂₃H₃₇N₂O₇PSNa 539.1951, found 539.1972. Elemental analysis (%) calcd for C₂₃H₃₇N₂O₇PS: C 53.48, H 7.22, N 5.42. Found: C 53.67, H 7.45, N 5.37.

Compound 2c. Yield 91%, 2.12 g; colorless oil: data for the major isomer (yield approximately 48%), $[\alpha]_D^{23}$ –14.2 (*c* 1.0, CHCl₃); IR (film) 3187, 2977, 2927, 2360, 1495, 1221, 1061, 1031, 702 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.33–7.21 (m, 5H), 5.06 (d, *J* = 9.6 Hz, 1H), 4.27 (m, 2H), 3.94–3.76 (m, 5H), 3.74 (s, 2H), 3.69 (m, 1H), 3.06 (m, 1H), 2.74 (m, 1H), 1.34 (t, *J* = 7.2 Hz, 3H), 1.29–1.21 (m,

15H); ¹³C NMR (CDCl₃, 100 MHz) δ 138.0 (s), 129.0 (s), 128.6 (s), 127.2 (s), 99.7 (d, *J* = 140.7 Hz), 66.2 (d, *J* = 10.9 Hz) and 65.2 (d, *J* = 8.8 Hz), 62.9 (d, *J* = 6.5 Hz), 57.3 (s), 52.2 (d, *J* = 86.1 Hz), 36.8 (s), 33.0 (d, *J* = 4.4 Hz), 22.8 (s), 16.7 (d, *J* = 4.3 Hz), 15.4 (d, *J* = 6.6 Hz); ³¹P NMR (CDCl₃, 162 MHz) δ 36.59; MS (ESI) *m/z* (%) 466.1 [M + H]⁺; HRMS (ESI) Calcd for C₂₀H₃₆NO₅PS₂Na 488.1665, found 488.1667. Elemental analysis (%) calcd for C₂₀H₃₆NO₅PS₂: C 51.59, H 7.79, N 3.01. Found: C 51.25, H 7.89, N 3.03.

Compound 2*d*. Yield 90%, 2.49 g; light yellow oil: $[\alpha]_D^{23}$ 3.1 (*c* 1.0, CHCl₃); IR (film) 3190, 2977, 2927, 2863, 1476, 1448, 1218, 1060, 1033, 743 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.73 (m, 2H), 7.67 (m, 2H), 7.37 (t, *J* = 7.2 Hz, 2H), 7.30 (m, 2H), 5.11–4.75 (m, 1H), 4.27 (m, 2H), 4.12 (t, *J* = 5.6 Hz, 1H), 3.96–3.53 (m, 6H), 3.22–2.78 (m, 4H), 1.34 (t, *J* = 6.8 Hz, 3H), 1.29–1.24 (m, 6H), 1.22–1.21 (m, 9H); ¹³C NMR (CDCl₃, 100 MHz) δ 145.9 (m), 141.2 (m), 127.6 (s), 127.0 (s), 124.9 (m), 119.9 (m), 100.3 (m), 66.3 (m) and 65.3 (m), 62.9 (m), 57.4 (m), 52.3 (m), 46.8 (m), 37.0 (m), 34.5 (m), 22.7 (m), 16.7 (m), 15.4 (m); ³¹P NMR (CDCl₃, 162 MHz) δ 37.22, 37.16, 36.95, 36.69; MS (ESI) *m*/*z* (%) 554.3 [M + H]⁺; HRMS (ESI) Calcd for C₂₇H₄₀NO₅PS₂Na 576.1978, found 576.1979.

Compound **2e.** Yield 87%, 1.81 g; colorless oil: $[\alpha]_D^{27}$ 37.5 (*c* 1.0, CHCl₃); IR (film) 3459, 3203, 2978, 1737, 1440, 1390, 1366, 1302, 1213, 1163, 1061, 959, 838, 593 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) *δ* 5.10 (m, 1H), 4.29 (m, 2H), 4.0–3.72 (m, 6H), 3.68 (s, 3H), 2.78–2.45 (m, 2H), 2.29 (m, 1H), 1.98 (m, 1H), 1.37 (t, *J* = 6.8 Hz, 3H), 1.30–1.25 (m, 15H); ¹³C NMR (CDCl₃, 100 MHz) *δ* for the major isomer, 173.0 (s), 99.7 (d, *J* = 140.0 Hz), 66.5 (d, *J* = 9.5 Hz) and 65.2 (d, *J* = 9.5 Hz), 62.7 (d, *J* = 7.3 Hz), 56.7 (s), 51.5 (s), 51.4 (d, *J* = 89.7 Hz), 30.2 (d, *J* = 8.8 Hz), 25.3 (d, *J* = 2.9 Hz), 22.6 (s) 16.5 (d, *J* = 5.1 Hz), 15.2 (m); ³¹P NMR (CDCl₃, 121 MHz) *δ* 39.94, 39.41, 38.89, 38.64; ESI (*m*/*z*) 416.5 [M + H]⁺; HRMS (ESI) Calcd for C₁₆H₃₄NO₇PSNa 438.1686, found 438.1707. Elemental analysis (%) calcd for C₁₆H₃₄NO₇PS: C 46.25; H 8.25; N 3.37. Found: C 46.04; H 8.37; N 3.22.

Compound 2f. Yield 59%, 1.14 g; colorless oil: $[\alpha]_D^{27}$ 76.5 (*c* 1.1, CHCl₃); IR (film) 3479, 3334, 2974, 2931, 2876, 1644, 1462, 1390, 1365, 1216, 1061, 958, 870, 559, 497 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 5.16 (d, *J* = 7.2 Hz, 1H), 4.28 (m, 2H), 3.96–3.65 (m, 6H), 2.11 (m, 1H), 1.70 (m, 1H), 1.35 (m, 3H), 1.31–1.25 (m, 15H), 1.21 (m, 1H), 1.01 (m, 3H), 0.92 (m, 3H); ¹³C NMR (CDCl₃, 100 MHz) δ 99.0 (d, *J* = 137.8 Hz), 65.9 (d, *J* = 11 Hz) and 64.8 (d, *J* = 8.0 Hz), 62.4 (d, *J* = 7.3 Hz), 57.2 (d, *J* = 86.0 Hz), 57.0 (s), 35.9 (d, *J* = 2.1 Hz), 24.3 (d, *J* = 1.4 Hz), 22.9 (s), 16.7 (d, *J* = 18.9 Hz), 16.6 (d, *J* = 5.1 Hz), 15.4 (d, *J* = 3.7 Hz), 11.9 (s); ³¹P NMR (CDCl₃, 162 MHz) δ 40.23, 39.10, 39.06, 37.90; ESI (*m*/*z*) 386.3 [M + H]⁺; HRMS (MALDI) Calcd for C₁₆H₃₇NO₅PS 386.2125, found 386.2123.

Compound **2g**. Yield 90%, 1.73 g; colorless oil: $[\alpha]_D^{25}$ 33.8 (*c* 1.2, CHCl₃); IR (film) 3466, 3188, 2957, 2870, 1500, 1387, 1366, 1294, 1215, 1062, 958, 795, 561 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 5.06 (d, *J* = 7.5 Hz, 1H), 4.18 (m, 2H), 3.87–3.58 (m, 6H), 1.78 (m, 1H), 1.52 (m, 2H), 1.28–1.08 (m, 18H), 0.84 (dd, *J*₁ = 4.5 Hz, *J*₂ = 19.5 Hz, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ 99.4 (d, *J* = 137.1 Hz), 65.9 (d, *J* = 9.4 Hz) and 64.9 (d, *J* = 8.8 Hz), 62.5 (d, *J* = 7.3 Hz), 56.9 (s), 50.7 (d, *J* = 89.7 Hz), 38.3 (d, *J* = 2.2 Hz), 23.8 (d, *J* = 10.2 Hz), 23.4 (s), 22.7 (s), 20.5 (s), 16.6 (d, *J* = 5.1 Hz), 15.3 (d, *J* = 6.6 Hz); ³¹P NMR (CDCl₃, 162 MHz) δ 39.92, 39.24, 38.70, 38.66; ESI (*m*/*z*) 386.3 [M + H]⁺; HRMS (ESI) Calcd for C₁₆H₃₇NO₃PS 386.2125, found 386.2109.

Compound 2h. Yield 94%, 2.49 g; colorless oil: $[\alpha]_D^{28}$ 20.8 (*c* 1.0, CHCl₃); IR (film) 3466, 3195, 2977, 2932, 1771, 1713, 1438, 1396, 1366, 1216, 1060, 958, 872, 722 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.76 (m, 2H), 7.64 (m, 2H), 5.03 (m, 1H), 4.19 (m, 2H), 3.80 (m, 4H), 3.67–3.53 (m, 4H), 1.88 (m, 1H), 1.61 (m, 4H), 1.35 (m, 1H), 1.27 (t, *J* = 6.8 Hz, 3H), 1.23–1.11 (m, 15H); ¹³C NMR (CDCl₃, 100 MHz) δ 168.3 (s), 133.9 (s), 132.1 (s), 123.2 (s), 99.6 (d, *J* = 138.6 Hz), 66.1 (d, *J* = 10.2 Hz) and 65.2 (d, *J* = 8.7 Hz), 62.6 (d, *J* = 7.3 Hz), 56.8 (s), 52.3 (d, *J* = 89.0 Hz), 37.6 (s), 29.3 (s), 28.2 (s), 23.3 (d, *J* = 9.5 Hz), 22.6 (s), 16.6 (d, *J* = 4.3 Hz), 15.4 (m); ³¹P NMR (CDCl₃, 162 MHz) δ 39.27, 38.92, 38.39, 38.0; ESI (*m*/*z*) 531.5 [M +

H]^; HRMS (ESI) Calcd for $C_{24}H_{39}N_2O_7PSNa$ 553.2108, found 553.2104.

Compound 2i. Yield 98%, 1.49 g; colorless oil: $[\alpha]_D^{25}$ 23.5 (*c* 2.0, CHCl₃); IR (film) 3448, 3192, 2978, 2919, 1475, 1443, 1390, 1296, 1216, 1163, 1060, 960, 562 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 5.10 (d, *J* = 9.6 Hz, 1H), 4.28 (m, 2H), 3.95–3.72 (m, 6H), 2.72 (m, 2H), 2.09 (m, 1H), 2.09 (s, 3H), 1.91 (m, 1H), 1.36 (t, *J* = 6.8 Hz, 3H), 1.29 (m, 6H), 1.25 (s, 9H); ¹³C NMR (CDCl₃, 100 MHz) δ 99.7 (d, *J* = 139.2 Hz), 66.1 (d, *J* = 9.5 Hz) and 65.1 (d, *J* = 8.7 Hz), 62.7 (d, *J* = 7.2 Hz), 56.8 (s), 51.0 (d, *J* = 89.7 Hz), 30.2 (d, *J* = 10.9 Hz), 29.6 (d, *J* = 2.1 Hz), 22.7 (s), 16.7 (d, *J* = 5.1 Hz), 15.3 (d, *J* = 3.7 Hz), 15.0 (s); ³¹P NMR (CDCl₃, 162 MHz) δ 39.12, 38.80, 38.29, 37.95; ESI (*m*/*z*) 404.3 [M + H]⁺. Elemental analysis (%) calcd for C₁₅H₃₄NO₅PS₂: C 44.65; H 8.49; N 3.47. Found: C 44.21; H 8.72; N 3.34.

Compound **2j**. Yield 64%, 1.34 g; colorless oil: $[\alpha]_D^{26}$ 3.9 (*c* 1.0, CHCl₃); IR (film) 3446, 3184, 3063, 2978, 2929, 1475, 1214, 1166, 1060, 959, 598 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.44–7.19 (m, SH), 5.03 (m, 1H), 4.28 (m, 2H), 4.10–3.64 (m, 6H), 3.09 (m, 2H), 1.39–0.92 (m, 18H); ¹³C NMR (CDCl₃, 100 MHz) δ 137.4 (d, *J* = 11.7 Hz), 129.5 (m), 128.4 (m), 126.7 (m), 99.7 (d, *J* = 137.8 Hz), 66.2 (m) and 65.2 (d, *J* = 8.7 Hz), 62.9 (m), 56.7 (m), 53.9 (m), 36.0 (d, *J* = 4.4 Hz), 22.4 (m), 16.7 (m), 15.3 (m); ³¹P NMR (CDCl₃, 162 MHz) δ 66.34, 65.24, 64.93, 64.84; ESI (*m*/*z*) 420.3 [M+ H]⁺. Elemental analysis (%) calcd for C₁₉H₃₄NO₅PS: C 54.40; H 8.17; N 3.34. Found: C 54.51; H 8.26; N 2.94.

Compound **2l**. Yield 50%, 1.12 g; colorless oil: $[\alpha]_D^{21}$ 36.4 (*c* 1.0, CHCl₃); IR (film) 3177, 2978, 2929, 2869, 1476, 1455, 1364, 1217, 1108, 1060, 958, 738, 700 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.40–7.28 (m, 5H), 5.0 (m, 1H), 4.54 (m, 2H), 4.39–3.94 (m, 4H), 3.93–3.72 (m, 5H), 3.60 (m, 1H), 1.35–1.21 (m, 18H); ¹³C NMR (CDCl₃, 100 MHz) δ for the major isomer, 137.6 (s), 128.4 (s), 128.0 (s), 127.8 (s), 99.8 (d, *J* = 145.2 Hz), 73.5 (s), 69.0 (s), 66.0 (d, *J* = 10.9 Hz) and 65.5 (d, *J* = 8.7 Hz), 62.6 (d, *J* = 7.3 Hz), 56.6 (s), 52.3 (d, *J* = 88.2 Hz), 22.5 (s), 16.6 (m), 15.4 (m); ³¹P NMR (CDCl₃, 121 MHz) δ 38.26, 38.21, 37.89, 37.33; ESI (*m*/*z*) 450.3 [M + H]⁺; HRMS (ESI) calcd for C₂₀H₃₇NO₆PS 450.2074, found 450.2072.

Compound (-)-2l. Yield 88%, 1.98 g; colorless oil: $[\alpha]_D^{27}$ -34.4 (c 1.0, CHCl₃); IR (film) 3486, 3182, 2978, 2870, 1641, 1476, 1455, 1364, 1301, 1218, 1106, 1058, 959, 739, 700, 560 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.38–7.28 (m, 5H), 5.0 (m, 1H), 4.54 (m, 2H), 4.22 (m, 2H), 4.15–3.71 (m, 7H), 3.60 (m, 1H), 1.35–1.21 (m, 18H); ¹³C NMR (CDCl₃, 100 MHz) δ for the major isomer, 137.6 (s), 128.3 (s), 127.9 (s), 127.8 (s), 99.7 (d, *J* = 145.1 Hz), 73.4 (s), 68.9 (s), 65.9 (d, *J* = 10.2 Hz) and 65.4 (d, *J* = 8.8 Hz), 62.5 (d, *J* = 7.3 Hz), 56.5 (s), 52.3 (d, *J* = 88.3 Hz), 22.4 (s), 16.5 (m), 15.3 (m); ³¹P NMR (CDCl₃, 162 MHz) δ 37.03, 36.68, 36.13; ESI (*m*/*z*) 450.5 [M + H]⁺; HRMS (ESI) calcd for C₂₀H₃₆NO₆PSNa 472.1893, found 472.1896.

Compound **2m**. Yield 92%, 2.13 g; colorless oil: $[\alpha]_{D}^{26}$ 29.1 (*c* 1.0, CHCl₃); IR (film) 3478, 2977, 2929, 1455, 1390, 1217, 1060 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.40–7.26 (m, 5H), 5.27–4.67 (m, 1H), 4.62 (m, 1H), 4.48 (m, 1H), 4.31 (m, 1H), 4.26–2.84 (m, 8H), 1.53–1.12 (m, 21H); ¹³C NMR (CDCl₃, 100 MHz) δ 138.0 (m), 128.1 (m), 127.7 (m), 127.3 (m), 100.6 (m), 77.1 (m), 72.1 (m), 67.3 (m), 64.8 (m), 62.3 (m), 57.1 (m), 22.7 (m), 16.8 (m), 16.3 (m), 15.2 (m); ³¹P NMR (CDCl₃, 162 MHz) δ 38.37, 37.12, 36.53, 35.58; ESI (*m/z*) 464.4 [M + H]⁺; HRMS (MALDI) calcd for C₂₁H₃₈NO₆PSNa 486.2050, found 486.2035.

Compound 2n. Yield 93%, 2.13 g; sticky yellow oil: $[\alpha]_D^{26}$ 4.7 (c 1.0, CHCl₃); IR (film) 3244, 2978, 2929, 1456, 1206, 1058, 960, 742 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 8.43 (s, 1H), 7.65 (m, 1H), 7.35 (d, *J* = 8.0 Hz, 1H), 7.17 (dt, *J*₁ = 0.4 Hz, *J*₂ = 7.2 Hz, 1H), 7.13–7.07 (m, 2H), 4.79 (d, *J* = 10.4 Hz, 1H), 4.28 (m, 2H), 4.15 (m, 1H), 3.95–3.65 (m, 4H), 3.43 (m, 2H), 3.14 (m, 1H), 1.38–1.24 (m, 6H), 1.18 (t, *J* = 7.2 Hz, 3H), 0.97 (s, 9H); ¹³C NMR (CDCl₃, 100 MHz) δ for the major isomer, 136.3 (s), 127.6 (s), 123.6 (s), 122.0 (s), 119.5 (s), 118.9 (s), 111.2 (s), 111.0 (s), 100.2 (d, *J* = 137.9 Hz), 66.3 (d, *J* = 8.8 Hz) and 65.3 (d, *J* = 10.3 Hz), 62.8 (d, *J* = 7.3 Hz), 56.6 (s), 52.7 (d, *J* = 88.2 Hz), 26.1 (d, *J* = 3.7 Hz), 22.3 (s), 16.6 (d, *J* = 5.1 Hz), 15.3 (d, *J* = 14.6 Hz); ³¹P NMR (CDCl₃, 121 MHz) δ 39.54, 38.72; ESI (m/z) 459.2 $[M + H]^+$; HRMS (ESI) Calcd for $C_{21}H_{35}N_2O_5PSNa$ 481.1897, found 481.1913. Elemental analysis (%) calcd for $C_{21}H_{35}N_2O_5PS$: C 55.00; H 7.69; N 6.11. Found: C 54.68; H 7.92; N 5.93.

Compound 20. Yield 96%, 2.16 g; colorless oil: $[α]_D^{-26}$ 1.4 (*c* 1.3, CHCl₃); IR (film) 3184, 2978, 2931, 1613, 1514, 1456, 1391, 1248, 1060, 960, 831 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.14 (m, 2H), 6.83 (m, 2H), 5.01 (d, *J* = 10.4 Hz, 1H), 4.26 (m, 2H), 4.2–3.6 (m, 6H), 3.78 (s, 3H), 3.34–2.76 (m, 2H), 1.39–0.96 (m, 18H); ¹³C NMR (CDCl₃, 100 MHz) δ for the major isomer, 158.5 (s), 130.7 (s), 129.2 (d, *J* = 11.6 Hz), 113.8 (s), 99.7 (d, *J* = 138.6 Hz), 66.2 (d, *J* = 10.3 Hz) and 65.1 (d, *J* = 8.7 Hz), 62.7 (d, *J* = 7.3 Hz), 56.6 (s), 55.3 (s), 54.1 (d, *J* = 8.9 Hz); ³¹P NMR (CDCl₃, 162 MHz) δ 36.52, 35.46, 35.25, 35.02; ESI (*m*/*z*) 450.4 [M + H]⁺; HRMS (ESI) Calcd for C₂₀H₃₆NO₆PSNa 472.1893, found 472.1915. Elemental analysis (%) calcd for C₂₀H₃₆NO₆PS. C 53.44; H 8.07; N 3.12. Found: C 53.12; H 8.18; N 2.97.

Compound **2p**. Yield 70%, 1.30 g; colorless oil: $[a]_D^{25}$ 44.5 (*c* 0.67, CHCl₃); IR (film) 3480, 3000, 2931, 2875, 1653, 1475, 1390, 1366, 1213, 1059, 952, 599 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 5.22–4.74 (m, 1H), 4.76–3.50 (m, 8H), 2.5–2.2 (m, 1H), 1.38–1.26 (m, 24H); ¹³C NMR (CDCl₃, 75 MHz) δ 99.6 (m), 67.7–64.8 (m), 63.4–62.3 (m), 58.4–55.2 (m), 57.2 (s), 30.3–28.2 (m), 23.0–22.9 (m), 20.8 (m), 16.9 (m), 15.4 (m); ³¹P NMR (CDCl₃, 162 MHz) δ 39.87, 38.95, 38.86, 37.70; ESI (*m*/z) 372.1 [M + H]⁺; HRMS (MALDI) Calcd for C₁₅H₃₅NO₅PS 372.1968, found 372.1954.

Compound **2q**. **2q** was prepared from **2e**. To **2e** (420 mg, 1 mmol) was added 10 mL of aqueous ammonia and stirred overnight. The reaction was extracted by chloroform (20 mL × 5), washed with brine and then dried over anhydrous Na₂SO₄. The crude product was purified by column chromatography giving 267 mg colorless oil in 67% yield: $[\alpha]_D^{25}$ 40.8 (*c* 1.0, CHCl₃); IR (film) 3369, 3196, 2978, 1673, 1213, 1057, 594 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 6.80 (br, 1H), 6.28 (br, 1H), 5.03 (m, 1H), 4.69–4.41 (m, 1H), 4.27 (m, 2H), 3.90 (m, 2H), 3.83–3.65 (m, 3H), 2.52 (m, 1H), 2.42 (m, 1H), 2.25 (m, 1H), 2.05 (m, 1H), 1.38–1.25 (m, 18H); ¹³C NMR (CDCl₃, 100 MHz) δ for the major isomer, 175.2 (s), 99.7 (d, *J* = 139.3 Hz), 66.3 (d, *J* = 9.5 Hz) and 65.7 (d, *J* = 9.5 Hz), 62.9 (d, *J* = 7.3 Hz), 55.8 (s), 51.6 (d, *J* = 91.1 Hz), 31.9 (d, *J* = 8.0 Hz), 26.1 (s), 22.6 (s), 16.6 (m), 15.3 (m); ³¹P NMR (CDCl₃, 162 MHz) δ 39.22, 38.60, 38.44, 38.15; ESI (*m*/*z*) 401.4 [M + H]⁺; HRMS (ESI) Calcd for C₁₅H₃₄N₂O₆PS 401.1870, found 401.1878.

Compound 2r. 2r was prepared from 2e. To 2e (414 mg, 1 mmol) in 5 mL of MeOH, 5 mL of BnNH₂ was added and stirred for 2 days. The solution was concentrated and then purified by column chromatography with DCM:MeOH (NH₃) (50:1), giving 467 mg colorless oil in 95% yield: $[\alpha]_D^{25}$ 33.9 (*c* 1.0, CHCl₃); IR (film) 3281, 2977, 1655, 1546, 1215, 1058, 699 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.33–7.23 (m, 5H), 6.89–6.70 (m, 1H), 5.03 (m, 1H), 4.41 (m, 2H), 4.23 (m, 2H), 4.11 (m, 1H), 3.87 (m, 2H), 3.80–3.56 (m, 3H), 2.52 (m, 1H), 2.42 (m, 1H), 2.26 (m, 1H), 2.09 (m, 1H), 1.35–1.22 (m, 18H); ¹³C NMR (CDCl₃, 100 MHz) δ for the major isomer, 172.1 (s), 138.5 (s), 128.6 (s), 127.7 (s), 127.3 (s), 99.9 (d, *J* = 140.0 Hz), 66.3 (d, *J* = 9.5 Hz) and 65.7 (d, *J* = 9.5 Hz), 62.8 (d, *J* = 7.3 Hz), 56.8 (s), 51.4 (d, *J* = 91.2 Hz), 43.4 (s), 32.8 (d, *J* = 7.3 Hz), 26.8 (s), 22.6 (s), 16.6 (d, *J* = 5.1 Hz), 15.3 (d, *J* = 5.8 Hz); ³¹P NMR (CDCl₃, 162 MHz) δ 38.97, 38.30, 38.25, 37.64; ESI (*m*/*z*) 491.5 [M + H]⁺; HRMS (ESI) Calcd for C₂₂H₄₀N₂O₆PS 491.2339, found 491.2347.

Procedure for Preparation of 3. To 0.5 mmol phosphinate 2, 2.5 mL of 4 M HCl in MeOH was added at room temperature. After 75 min, the reaction monitored by TLC was completed. The solution was concentrated under a vacuum and then dissolved in DCM. MeOH saturated with ammonia was added to neutralize the residual acid. The crude product was purified by silica gel column chromatography with DCM/MeOH (NH₃) (50:1) to give phosphinate **3**.

Compound **3b**. Yield >99%, 206 mg; colorless oil: $[\alpha]_D{}^{30}$ 1.0 (*c* 0.97, CHCl₃); IR (film) 3595, 3462, 3384, 2977, 2932, 1771, 1716, 1440, 1397, 1370, 1213, 1034, 722 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.83 (m, 2H), 7.72 (m, 2H), 4.88 (d, *J* = 7.2 Hz, 1H), 4.21

(m, 2H), 3.87 (m, 2H), 3.71 (m, 4H), 3.10 (m, 1H), 2.06 (m, 1H), 1.91 (m, 1H), 1.82 (m, 1H), 1.53 (m, 1H), 1.42 (m, 2H), 1.33 (m, 3H), 1.24 (m, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ for the major isomer, 168.2 (s), 133.8 (s), 132.0 (s), 123.0 (s), 100.6 (d, *J* = 132.0 Hz), 65.4 (m), 61.7 (m), 48.6 (d, *J* = 91.1 Hz), 37.5 (s), 27.3 (d, *J* = 9.5 Hz), 25.2 (d, *J* = 11.7 Hz), 16.6 (m), 15.1 (m); ³¹P NMR (CDCl₃, 162 MHz) δ 41.44, 41.14; MS (ESI) *m/z* (%) 413.3 [M + H]⁺; HRMS (ESI) Calcd for C₁₉H₃₀N₂O₆P 413.1836, found 413.1852. Analysis of ³¹P NMR and HPLC spectra of (*S*)-Mosher's derivate **6b**: retention time = 148.6 min, 170.6 min (89.9:10.1).

Compound **3c**. Yield 90%, 162 mg, colorless oil: $[\alpha]_D^{30}$ –50.3 (*c* 1.0, CHCl₃); IR (film) 3370, 3292, 1221, 1109, 1057, 1035, 701 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.34–7.22 (m, 5H), 4.87 (d, *J* = 7.2 Hz, 1H), 4.21 (m, 2H), 3.85 (m, 2H), 3.74 (s, 2H), 3.66 (m, 2H), 3.19 (m, 1H), 3.06 (m, 1H), 2.56 (m, 1H), 1.31 (t, *J* = 6.8 Hz, 3H), 1.23 (m, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ 138.2 (s), 128.9 (s), 128.6 (s), 127.1 (s), 100.4 (d, *J* = 136.4 Hz), 65.7 (d, *J* = 8.0 Hz) and 65.4 (d, *J* = 8.7 Hz), 62.1 (d, *J* = 7.3 Hz), 48.8 (d, *J* = 93.3 Hz), 36.5 (s), 33.6 (d, *J* = 3.7 Hz), 16.7 (d, *J* = 4.3 Hz), 15.3 (d, *J* = 5.1 Hz); ³¹P NMR (CDCl₃, 162 MHz) δ 39.84; MS (ESI) *m*/*z* (%) 362.1 [M + H]⁺; HRMS (ESI) Calcd for C₁₆H₂₈NO₄PSNa 384.1369, found 384.1383. Elemental analysis (%) calcd for C₁₆H₂₈NO₄PS: C 53.17, H 7.81, N 3.88. Found: C 52.88, H 7.79, N 3.95.

Compound **3d**. Yield 82%, 184 mg; colorless oil: $[\alpha]_D^{24} - 16.5$ (*c* 1, CHCl₃); IR (film) 3063, 3039, 2977, 2928, 1477, 1448, 1295, 1216, 1108, 1057, 1034, 955, 744, 540 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.74 (d, *J* = 7.6 Hz, 2H), 7.70 (d, *J* = 7.2 Hz, 1H), 7.66 (d, *J* = 7.2 Hz, 1H), 7.38 (t, *J* = 7.2 Hz, 2H), 7.31 (t, *J* = 7.6 Hz, 2H), 4.89 (t, *J* = 7.6 Hz, 1H), 4.22 (m, 2H), 4.13 (t, *J* = 6.0 Hz, 1H), 3.86 (m, 2H), 3.68 (m, 2H), 3.27–3.02 (m, 4H), 2.65 (m, 1H), 1.70 (s, 2H), 1.32 (m, 3H), 1.23 (m, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ for the major isomer, 145.9 (s), 141.1 (d, *J* = 3.6 Hz), 127.6 (s), 127.1 (s), 124.8 (d, *J* = 18.3 Hz), 119.9 (s), 100.5 (d, *J* = 137.1 Hz), 65.8 (m), 62.3 (m), 48.6 (d, *J* = 93.3 Hz), 46.9 (s), 36.7 (s), 35.2 (s), 16.8 (d, *J* = 5.1 Hz), 15.3 (s); ³¹P NMR (CDCl₃, 162 MHz) δ 40.28, 39.89; MS (ESI) *m/z* (%) 450.3 [M + H]⁺; HRMS (ESI) Calcd for C₂₃H₃₃NO₄PS 450.1862, found 450.1845.

Compound **3e**. Yield 65%, 106 mg; colorless oil: $[\alpha]_D^{24} - 2.5$ (*c* 1.0, CHCl₃); IR (film) 3389, 2979, 2933, 2904, 1732, 1446, 1208, 1056, 1034, 956 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 4.86 (d, *J* = 7.2 Hz, 1H), 4.23 (m, 2H), 4.13 (q, *J* = 7.2 Hz, 2H), 3.88 (m, 2H), 3.71 (m, 2H), 3.08 (m, 1H), 2.62 (m, 1H), 2.51 (m, 1H), 2.20 (m, 1H), 1.80 (m, 1H), 1.64 (br, 2H), 1.35 (t, *J* = 6.8 Hz, 3H), 1.26 (m, 9H); ¹³C NMR (CDCl₃, 100 MHz) δ for the major isomer, 173.4 (s), 101.0 (d, *J* = 131.2 Hz), 65.8 (d, *J* = 8.0 Hz) and 65.6 (d, *J* = 9.7 Hz), 61.9 (d, *J* = 7.3 Hz), 60.4 (s), 48.6 (d, *J* = 89.7 Hz), 31.0 (d, *J* = 11.7 Hz), 25.5 (d, *J* = 3.6 Hz), 16.7 (d, *J* = 5.1 Hz), 15.2 (d, *J* = 2.9 Hz), 14.2 (s); ³¹P NMR (CDCl₃, 121 MHz) δ 42.32, 42.03; MS (ESI) *m/z* (%) 326.2 [M + H]⁺; HRMS (ESI) Calcd for C₁₃H₂₉NO₆P 326.1727, found 326.1717. Analysis of the ³¹P NMR and ¹⁹F NMR spectra of the (*S*)-Mosher's derivate **6e**: dr = 88:12.

Compound **3f**. Yield 82%, 115 mg; colorless oil: $[α]_D^{-24}$ 10.4 (*c* 1.0, CHCl₃); IR (film) 3391, 2974, 2932, 2876, 1213, 1112, 1058, 953 cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ 4.99 (d, *J* = 6.8 Hz, 1H), 4.24 (m, 2H), 4.92 (m, 2H), 3.74 (m, 2H), 3.13 (dd, *J*₁ = 4.0 Hz, *J*₂ = 6.8 Hz, 1H), 1.93 (m, 1H), 1.76 (m, 1H), 1.37 (t, *J* = 7.2 Hz, 3H), 1.28 (m, 7H), 1.07 (d, *J* = 36.4 Hz, 3H), 0.96 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (CD₃OD, 100 MHz) δ 100.7 (d, *J* = 181.2 Hz), 66.0 (d, *J* = 12.1 Hz) and 65.8 (d, *J* = 11.6 Hz), 62.0 (d, *J* = 10.2 Hz), 52.4 (d, *J* = 121.5 Hz), 35.6 (s), 24.1 (s), 15.6 (s), 15.5 (d, *J* = 5.9 Hz), 14.1 (d, *J* = 20.0 Hz), 10.8 (s); ³¹P NMR (CD₃OD, 121 MHz) δ 44.10, 43.80; MS (ESI) *m*/*z* (%) 282.2 [M + H]⁺; HRMS (ESI) Calcd for C₁₂H₂₉NO₄P 282.1829, found 282.1829.

Compound **3g**. Yield 90%, 126 mg; colorless oil: $[\alpha]_D^{26}$ –5.8 (*c* 1.0, CHCl₃); IR (film) 3380, 2957, 2931, 1389, 1204, 1113, 1057, 825 cm⁻¹; ¹H NMR (CDCl ₃, 400 MHz) δ 4.88 (d, *J* = 7.6 Hz, 1H), 4.23 (m, 2H), 3.89 (m, 2H), 3.71 (m, 2H), 3.16 (m, 1H), 1.96 (m, 1H), 1.56 (m, 1H), 1.46 (m, 1H), 1.35 (t, *J* = 7.2 Hz, 3H), 1.27 (t, *J* = 7.2 Hz, 6H), 0.97 (d, *J* = 6.8 Hz, 3H), 0.90 (d, *J* = 6.4 Hz, 3H); ¹³C NMR (CDCl ₃, 100 MHz) δ 100.7 (d, *J* = 131.3 Hz), 65.7 (d, *J* = 7.3 Hz)

and 65.3 (d, J = 8.8 Hz), 61.8 (d, J = 7.3 Hz), 46.8 (d, J = 91.9 Hz), 38.5 (s), 23.9 (d, J = 12.4 Hz), 23.6 (s) and 20.8 (s), 16.7 (d, J = 4.4 Hz), 15.2 (d, J = 5.8 Hz); ³¹P NMR (CDCl ₃, 162 MHz) δ 42.05; MS (ESI) m/z (%) 282.3 [M + H]⁺; HRMS (ESI) Calcd for C₁₂H₂₉NO₄P 282.1829, found 282.1831.

Compound 3h. Yield 79%, 168 mg; colorless oil: $[\alpha]_D^{26}$ -10.9 (*c* 1.8, CHCl₃); IR (film) 3237, 2976, 2931, 2866, 1771, 1713, 1397, 1120, 1056, 722 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.84 (dd, J_1 = 3.2 Hz, J_2 = 5.2 Hz, 2H), 7.71 (dd, J_1 = 2.8 Hz, J_2 = 5.2 Hz, 2H), 4.86 (d, J = 7.2 Hz, 1H), 4.21 (m, 2H), 3.87 (m, 2H), 3.71 (m, 4H), 3.04 (m, 1H), 1.89 (m, 1H), 1.78–1.68 (m, 3H), 1.47 (m, 2H), 1.33 (m, 3H), 1.26 (m, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ for the major isomer, 168.4 (s), 133.9 (s), 132.2 (s), 123.2 (s), 100.9 (d, J = 131.2 Hz), 65.7 (d, J = 8.1 Hz) and 65.6 (d, J = 8.8 Hz), 61.8 (m), 48.9 (d, J = 91.1 Hz), 37.8 (s), 29.6 (d, J = 6.6 Hz), 28.4 (s), 23.6 (d, J = 11.6 Hz), 16.7 (d, J = 4.4 Hz), 15.3 (m); ³¹P NMR (CDCl₃, 162 MHz) δ 40.96, 40.26; MS (ESI) m/z (%) 427.5 [M + H]⁺; HRMS (ESI) Calcd for C₂₀H₃₂N₂O₆P 427.1992, found 427.2012.

Compound **3i**. Yield 79%, 118 mg; colorless oil: $[\alpha]_D^{26}$ –8.8 (*c* 1.0, CHCl₃); IR (film) 3983, 2977, 2919, 1633, 1444, 1205, 1109, 1058, 957 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 4.87 (m, 1H), 4.23 (m, 2H), 3.88 (m, 2H), 3.70 (m, 2H), 3.38 (m, 1H), 2.80 (m, 1H), 2.68 (m, 1H), 2.16 (m, 1H), 2.11 (s, 3H), 1.76 (m, 1H), 1.35 (m, 3H), 1.27 (t, *J* = 7.2 Hz, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ for the major isomer, 101.0 (d, *J* = 132.0 Hz), 65.8 (d, *J* = 8.0 Hz) and 65.6 (d, *J* = 8.8 Hz), 61.9 (d, *J* = 8.0 Hz), 47.7 (d, *J* = 90.4 Hz), 30.8 (d, *J* = 13.1 Hz), 29.40 (s), 29.37 (s), 16.8 (d, *J* = 5.1 Hz), 15.2 (m); ³¹P NMR (CDCl₃, 121 MHz) δ 42.78, 42.55; MS (ESI) *m/z* (%) 300.3 [M + H]⁺; HRMS (MALDI) Calcd for C₁₁H₂₆NO₄PSNa 322.1212, found 322.1212.

Compound 3j. Yield >99%, 158 mg; light yellow oil: $[a]_{D}^{26}$ –9.6 (*c* 1.0, CHCl₃); IR (film) 3378, 2977, 2929, 1454, 1217, 1111, 1057, 953, 700 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.32 (m, 2H), 7.27–7.22 (m, 3H), 4.84 (m, 1H), 4.26 (m, 2H), 3.89 (m, 2H), 3.69 (m, 2H), 3.34 (m, 1H), 3.29 (m, 1H), 2.69 (m, 1H), 2.68 (m, 1H), 1.35 (t, *J* = 6.8 Hz, 3H), 1.27 (m, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ for the major isomer, 138.2 (d, *J* = 13.2 Hz), 129.4 (s), 128.6 (s), 126.6 (s), 100.7 (d, *J* = 136.3 Hz), 66.1 (d, *J* = 8.0 Hz) and 65.6 (d, *J* = 9.4 Hz), 62.1 (d, *J* = 7.3 Hz), 50.2 (d, *J* = 98.4 Hz), 36.6 (s), 16.8 (d, *J* = 5.1 Hz), 15.3 (d, *J* = 2.9 Hz); ³¹P NMR (CDCl₃, 162 MHz) δ 41.62, 41.22; MS (ESI) *m*/*z* (%) 316.3 [M + H]⁺; HRMS (ESI) Calcd for C₁₅H₂₇NO₄P 316.1672, found 316.1673.

Compound 3k. Yield 80%, 106 mg; colorless oil: $[\alpha]_D^{25}$ –1.8 (*c* 1.0, CHCl₃); IR (film) 3444, 2976, 2932, 2876, 1445, 1210, 1108, 1059, 958, 540 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 4.87 (m, 1H), 4.24 (m, 2H), 3.88 (m, 2H), 3.72 (m, 2H), 3.43 (m, 1H), 3.03 (m, 1H), 2.91 (m, 1H), 2.10–2.01 (m, 3H), 1.85 (m, 1H), 1.73 (m, 1H), 1.34 (t, *J* = 6.8 Hz, 3H), 1.26 (t, *J* = 7.2 Hz, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ for the major isomer, 100.3 (d, *J* = 140.1 Hz), 65.5 (m), 62.5 (d, *J* = 7.3 Hz), 53.6 (d, *J* = 101.3 Hz), 47.4 (d, *J* = 7.3 Hz), 25.6 (s), 25.5 (m), 16.6 (d, *J* = 5.1 Hz), 15.2 (d, *J* = 5.8 Hz); ³¹P NMR (CDCl₃, 121 MHz) δ 43.38, 42.90; MS (ESI) *m*/*z* (%) 266.6 [M + H]⁺; HRMS (ESI) Calcd for C₁₁H₂₅NO₄P 266.1516, found 266.1528.

Compound **3**l. Yield >99%, 173 mg; light yellow oil: $[α]_D^{26}$ 0.44 (*c* 1.0, CHCl₃); IR (film) 3453, 2977, 2929, 2870, 1478, 1454, 1212, 1106, 1068, 1035, 956, 740, 700, 556 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.34–7.27 (m, 5H), 4.83 (m, 1H), 4.55 (m, 2H), 4.21 (m, 2H), 3.80 (m, 4H), 3.62 (m, 2H), 3.40 (m, 1H), 1.30 (m, 3H), 1.22 (m, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ for the major isomer, 137.8 (s), 128.4 (s), 127.9 (s), 127.8 (s), 101.0 (d, *J* = 137.1 Hz), 73.5 (s), 70.0 (d, *J* = 19.6 Hz), 65.8 (m), 62.2 (m), 49.8 (d, *J* = 91.1 Hz), 16.7 (m), 15.2 (m); ³¹P NMR (CDCl₃, 162 MHz) δ 40.18, 39.95; MS (ESI) *m/z* (%) 346.3 [M + H]⁺; HRMS (MALDI) Calcd for C₁₆H₂₉NO₅P 346.1775, found 346.1773. Analysis of the ¹⁹F NMR and ³¹P NMR spectra of the (*S*)-Mosher's derivative **6**!: dr = 66.0:34.0.

Compound (-)-31. Yield >99%, 173 mg; light yellow oil: $[\alpha]_D^{27}$ 0.21 (c 1.0, CHCl₃); IR (film) 3453, 3385, 2988, 2871, 1641, 1604, 1454, 1212, 1106, 1058, 1034, 740, 700 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.33–7.28 (m, 5H), 4.83 (m, 1H), 4.54 (m, 2H), 4.21 (m, 2H), 3.80 (m, 4H), 3.60 (m, 2H), 3.40 (m, 1H), 1.29 (m, 3H), 1.21 (m, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ for the major isomer, 137.8 (s), 128.3 (s), 127.8 (s), 127.7 (s), 100.9 (d, J = 136.4 Hz), 73.4 (s), 69.9 (d, J = 2.9 Hz), 65.6 (m), 61.9 (d, J = 6.6 Hz), 49.7 (d, J = 91.9 Hz), 16.6 (m), 15.1 (m); ³¹P NMR (CDCl₃, 162 MHz) δ 40.05, 39.80 (1:0.8); MS (ESI) m/z (%) 346.3 [M + H]⁺; HRMS (MALDI) Calcd for C₁₆H₂₉NO₅P 346.1778, found 346.1787. Analysis of the ¹⁹F NMR and ³¹P NMR spectra of the (S)-Mosher's derivative (-)-**6**I: dr = 68.7:31.2.

Compound 3m. Yield 96%, 172 mg; colorless oil; the major isomer had a yield of about 45%, and it could be separated as single isomer with the following data: $\left[\alpha\right]_{D}^{23}$ -5.9 (c 1.0, CHCl₃); IR (film) 3455, 3389, 3310, 2977, 2930, 2898, 1606, 1454, 1392, 1219, 1034, 557 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.38–7.26 (m, 5H), 4.82 (d, J = 7.2 Hz, 1H), 4.64 (d, J = 10.8 Hz, 1H), 4.49 (d, J = 10.8 Hz, 1H), 4.16 (m, 1H), 4.08 (m, 2H), 3.85 (m, 2H), 3.64 (m, 2H), 3.15 (dd, $J_1 = 7.2$ Hz, $J_2 = 3.2$ Hz, 1H), 1.36 (dd, $J_1 = 6.0$ Hz, $J_2 = 0.8$ Hz, 3H), 1.23 (dt, $J_1 = 2.8$ Hz, $J_2 = 7.2$ Hz, 6H), 1.20 (t, J = 7.2 Hz, 3H); ¹³C NMR $(CDCl_3, 100 \text{ MHz}) \delta 138.4 \text{ (s)}, 128.3 \text{ (s)}, 128.0 \text{ (s)}, 127.6 \text{ (s)}, 100.8$ (d, J = 137.8 Hz), 72.9 (s), 71.0 (s), 65.5 (d, J = 8.8 Hz) and 65.3 (d, J = 8.7 Hz), 61.8 (d, J = 6.6 Hz), 54.4 (d, J = 91.1 Hz), 16.5 (d, J = 5.1 Hz), 16.3 (d, J = 8.8 Hz), 15.3 (s); ³¹P NMR (CDCl₃, 162 MHz) δ 40.14; MS (ESI) m/z (%) 360.2 [M + H]⁺; HRMS (MALDI) Calcd for C₁₇H₃₀NO₅PNa 382.1754, found 382.1746. Analysis of the ¹H NMR spectra of the (S)-Mosher's and (R)-Mosher's derivatives of 5mindicated the absolute configuration of (1R). But the configuration of the phosphorus atom could not be confirmed.

Compound **3n**. Yield 74%, 131 mg; light yellow oil: $[a]_D^{25} - 13.7$ (*c* 0.56, CHCl₃); IR (film) 3399, 3241, 2977, 1633, 1205, 1102, 1056, 1034, 742 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 8.45 (br, 1H), 7.64 (m, 1H), 7.37 (d, *J* = 8.0 Hz, 1H), 7.17 (m, 2H), 7.11 (m, 1H), 4.90–4.77 (m, 1H), 4.27 (m, 2H), 3.85 (m, 2H), 3.77–3.49 (m, 3H), 3.41 (m, 1H), 2.95 (m, 1H), 2.39 (br, 2H), 1.36 (m, 3H), 1.28–1.21 (m, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ 136.5 (s), 133.9 (s), 127.5 (d, *J* = 37.9 Hz), 123.6 (s), 122.1 (s), 119.5 (s), 118.9 (s), 111.4 (s), 100.7 (d, *J* = 134.9 Hz), 65.9 (d, *J* = 8.0 Hz) and 65.5 (d, *J* = 8.8 Hz), 62.3 (d, *J* = 7.3 Hz), 49.1 (d, *J* = 94.8 Hz), 26.2 (s), 16.8 (m), 15.3 (m); ³¹P NMR (CDCl₃, 162 MHz) δ 41.23, 40.89; MS (ESI) *m/z* (%) 355.1 [M + H]⁺; HRMS (MALDI) Calcd for C₁₇H₂₇N₂O₄PNa 377.1601, found 377.1599. Analysis of the ¹⁹F NMR and ³¹P NMR spectra of the (*S*)-Mosher's derivative **6n** indicated the dr value was 94.8:5.2.

Compound **3p**. Yield 98%, 131 mg; colorless oil: $[\alpha]_D^{26}$ 3.9 (*c* 1.2, CHCl₃); IR (film) 3390, 2975, 2931, 1208, 1113, 1057, 952, 551 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 4.87 (m, 1H), 4.23 (m, 2H), 3.89 (m, 2H), 3.71 (m, 2H), 3.0 (m, 1H), 2.25 (m, 1H), 1.34 (t, *J* = 6.8 Hz, 3H), 1.26 (m, 6H), 1.08–1.0 (m, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ 100.9 (d, *J* = 131.3 Hz), 65.6 (m), 61.6 (d, *J* = 7.3 Hz), 53.4 (d, *J* = 90.4 Hz), 27.7 (m), 20.8 (m), 17.0 (m), 15.3 (m); ³¹P NMR (CDCl₃, 162 MHz) δ 42.32, 41.82; MS (ESI) *m/z* (%) 268.3 [M + H]⁺; HRMS (ESI) Calcd for C₁₁H₂₇NO₄P 268.1672, found 268.1674. Analysis of the ¹H NMR, ¹⁹F NMR and ³¹P NMR spectra of the (*S*)-Mosher's derivative **6p** indicated the dr value was >95:5.

Compound 3q. 3q was prepared from 2q by the conditions of 4 M HCl/MeOH in a yield of 66% or from 3e as the following procedure. 3e (34 mg, 0.1 mmol) was dissolved in 10 mL of MeOH, which was previously saturated with NH3 at room temperature. The reaction was stirred overnight. Then the solution was concentrated to give 30 mg colorless oil in quantitative yield: $[\alpha]_{D}^{28}$ 10.4 (c 1.0, CHCl₃); IR (film) 3434, 3234, 2979, 1699, 1209, 1106, 1056, 544 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) & 6.12-6.05 (m, 1H), 4.81 (m, 1H), 4.23 (m, 2H), 3.98 (m, 1H), 3.87 (m, 2H), 3.71 (m, 2H), 2.55-2.30 (m, 4H), 1.35 (m, 3H), 1.28 (m, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ for the major isomer, 177.9 (d, J = 3.7 Hz), 101.2 (d, J = 140.0 Hz), 66.2 (m), 62.6 (d, J = 7.3 Hz), 49.6 (d, J = 100.6 Hz), 29.2 (d, J = 2.2 Hz), 20.4 (d, J = 3.7 Hz), 16.7 (d, J = 5.1 Hz), 15.2 (d, J = 4.4 Hz); ³¹P NMR $(\text{CDCl}_{3}, 162 \text{ MHz}) \delta 38.28, 39.10; \text{ MS} (\text{ESI}) m/z$ (%) 302.2 [M + Na]⁺; HRMS (ESI) Calcd for C₁₁H₂₂NO₅PNa 302.1128, found 302.1134.

Compound 3r. 3r was prepared by the reaction of 2r with 2.3 M HCl in EtOAc instead of 4 M HCl in MeOH. Yield 39%, 73 mg; colorless oil: $[\alpha]_D^{26}$ 2.6 (c 1.0, CHCl₃); IR (film) 3282, 2977, 2930,

1657, 1548, 1206, 1056, 956, 699 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.33–7.23 (m, 5H), 6.80 (br, 1H), 4.84 (m, 1H), 4.41 (d, *J* = 5.6 Hz, 2H), 4.18 (m, 2H), 3.85 (m, 2H), 3.68 (m, 2H), 3.08 (m, 1H), 2.53 (m, 1H), 2.44 (m, 1H), 2.19 (m, 1H), 1.85 (m, 1H), 1.32 (t, *J* = 6.8 Hz, 3H), 1.24 (t, *J* = 6.8 Hz, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ 172.5 (d, *J* = 3.6 Hz), 138.5 (s), 128.6 (s), 127.7 (s), 127.3 (s), 100.8 (d, *J* = 133.4 Hz), 65.8 (m), 62.0 (m), 48.4 (d, *J* = 90.4 Hz), 43.5 (s), 33.2 (d, *J* = 10.2 Hz), 26.6 (d, *J* = 3.0 Hz), 16.7 (d, *J* = 4.4 Hz), 15.3 (d, *J* = 3.7 Hz); ³¹P NMR (CDCl₃, 162 MHz) δ 41.3; MS (ESI) *m/z* (%) 387.5 [M + H]⁺; HRMS (ESI) Calcd for C₁₈H₃₂N₂O₅P 387.2043, found 387.2025.

Compound 3s. The product was obtained after the removal of the benzyl group of 31 according to the following procedure. 31 (37 mg, 0.1 mmol) was dissolved in 3.8 mL of EtOH, and 1.2 mL of THF, $Pd(OH)_2/C$ (37 mg, 20%, moisture) and TFA (41 μ L, 0.5 mmol) were added subsequently. The reaction was stirred under hydrogen at 27 °C overnight. After the completion of the reaction, the mixture was filtered through Celite and washed by ethyl acetate. The solution was concentrated and then purified by silica gel column chromatography with DCM/MeOH (NH₃) (30:1) to give 23 mg colorless oil in a yield of 90%: $[\alpha]_D^{27}$ 2.2 (c 1.0, CHCl₃); IR (film) 3373, 2978, 2931, 1680, 1445, 1394, 1203, 1110, 1056, 958, 560 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 4.84 (m, 1H), 4.24 (m, 2H), 3.88 (m, 4H), 3.72 (m, 2H), 3.25 (m, 1H), 2.36 (br, 3H), 1.36 (m, 3H), 1.27 (t, J = 6.8 Hz, 6H); $^{13}\mathrm{C}$ NMR (CDCl_3, 100 MHz) δ 101.2 (d, J = 137.1 Hz), 66.2 (m), 62.3 (m), 61.9 (m), 50.9 (d, J = 89.7 Hz), 16.7 (s), 15.2 (s); ³¹P NMR $(\text{CDCl}_3, 162 \text{ MHz}) \delta 41.36, 40.82; \text{ MS} (\text{ESI}) m/z (\%) 256.1 [M +$ H]⁺; HRMS (ESI) Calcd for C₉H₂₃NO₅P 256.1308, found 256.1309.

Compound (–)-3s. The product was obtained similar to that for 3s as a colorless oil. Yield 76%, 19 mg; colorless oil: $[\alpha]_D^{27}$ –2.4 (*c* 1.0, CHCl₃); IR (film) 3370, 2977, 2931, 1393, 1203, 1107, 1056, 957 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 4.85 (m, 1H), 4.24 (m, 2H), 3.88 (m, 4H), 3.72 (m, 2H), 3.27 (m, 1H), 2.73 (br, 3H), 1.35 (t, *J* = 7.2 Hz, 3H), 1.27 (t, *J* = 7.2 Hz, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ 101.2 (d, *J* = 137.1 Hz), 66.2 (m), 62.3 (m), 61.7 (m), 50.9 (d, *J* = 87.5 Hz), 16.7 (s), 15.2 (s); ³¹P NMR (CDCl₃, 162 MHz) δ 41.14, 40.71; the rest data are the same as compound 3s.

Compound **3t**. The product was obtained after the removal of the benzyl group from the single isomer of **3m** similar to that of **3s**. Yield 87%, 23 mg; colorless oil: $[\alpha]_D^{21}$ 4.1 (*c* 0.44, CHCl₃); IR (film) 3378, 2976, 2931, 1446, 1393, 1204, 1104, 1058, 669 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 4.83 (d, *J* = 6.4 Hz, 1H), 4.32–4.18 (m, 3H), 3.89 (m, 2H), 4.16 (m, 1H), 3.72 (m, 2H), 3.06 (dd, *J*₁ = 4.8 Hz, *J*₂ = 8.0 Hz, 1H), 1.38–1.33 (m, 6H), 1.27 (t, *J* = 7.2 Hz, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ 101.3 (d, *J* = 135.3 Hz), 66.3 (d, *J* = 8.6 Hz) and 66.0 (d, *J* = 8.6 Hz), 65.6 (d, *J* = 2.0 Hz), 62.3 (d, *J* = 7.5 Hz), 54.0 (d, *J* = 87.5 Hz), 19.8 (d, *J* = 9.1 Hz), 16.7 (d, *J* = 4.9 Hz), 15.2 (d, *J* = 2.9 Hz); ³¹P NMR (CDCl₃, 162 MHz) δ 40.61; MS (ESI) *m/z* (%) 270.1 [M + H]⁺; HRMS (ESI) Calcd for C₁₀H₂₅NO₅P 270.1465, found 270.1471.

Compound 9a. 9a was prepared from 3s according to the following procedure. 3s (93 mg, 0.36 mmol) dissolved in 2 mL of THF at 0 °C, then NEt₃ (0.1 mL, 0.72 mmol) was added. Boc₂O (0.17 mL, 0.72 mmol) in 0.8 mL of THF was added dropwise to the solution. After the reaction was stirred at 0 °C for 3 h, it was warmed to room temperature and stirred overnight. Then the solution was concentrated to give the crude product, which was directly subjected to next reaction. The crude product was dissolved in 6 mL of DCM, cooled to -15 °C, and then NEt₃ (0.15 mL, 1.08 mmol) and DMAP (44 mg, 0.36 mmol) were added. Then MsCl (0.14 mL, 1.8 mmol) in 1 mL of DCM was added dropwise. After about 3 h, the reaction was completed as indicated by TLC. Then 2 mL of diluted NaHCO₃ was added to quench the reaction. The aqueous phase was extracted with 10 mL \times 3 EtOAc. The combined organic phases were washed with brine and then dried over anhydrous Na2SO4. The crude product passed through a short silica gel column to remove byproducts and gave 119 mg colorless oil in 76% yield. The product (119 mg, 0.268 mmol) was dissolved in 5 mL of DMF, and NaCN (131 mg, 2.68 mmol) was added. The reaction was warmed to 40 °C. After 2 h, the solution turned yellow. The reaction was completed as indicated by

TLC. Twenty milliliters of EtOAc was added. The solution was washed by sat. FeSO₄ until the color of the organic phase remained. The organic phase was dried over anhydrous Na2SO4, and then purified by silica gel column chromatography with petroleum ether/ ethyl acetate (1:1 to 1:5) to give 49 mg light yellow oil in 54% yield: $[\alpha]_{D}^{22}$ 3.2 (c 1.0, CHCl₃); IR (film) 3244, 2979, 2933, 2248, 1717, 1522, 1367, 1167, 1059, 1033, 561 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 5.56-5.27 (m, 1H), 4.80 (m, 1H), 4.43 (m, 1H), 4.27 (m, 2H), 3.87 (m, 2H), 3.71 (m, 2H), 2.92 (m, 2H), 1.46 (s, 9H), 1.37 (m, 3H), 1.28 (m, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ for the major isomer, 155.0 (d, J = 7.3 Hz), 116.7 (d, J = 11.0 Hz), 101.7 (d, J = 146.6 Hz), 80.7 (s), 67.1 (d, J = 8.1 Hz) and 66.6 (d, J = 10.2 Hz), 63.3 (m), 44.4 (d, J = 97.7 Hz), 28.2 (s), 19.4 (d, J = 5.9 Hz), 16.6 (m), 15.2 (m); $^{31}\mathrm{P}$ NMR (CDCl₃, 162 MHz) δ 35.20, 34.73; MS (ESI) m/z (%) 387.1 [M + Na]⁺; HRMS (ESI) Calcd for C15H30N2O6P 365.1836, found 365.1847.

Compound 9b. 9b was prepared from 9a according to the following procedure. To 9a (25 mg, 0.068 mmol), a mixture of 1.6 mL of acetone, 0.13 mL of sat. Na2CO3, and 0.66 mL of H2O2 was added. After the reaction was stirred at room temperature for 2 days, the reaction was completed as indicated by TLC. The solution was concentrated, and the crude product was purified by silica gel column chromatography with DCM/MeOH(NH₃) (40:1) to give 22 mg of white sticky oil in 84% yield: $[\alpha]_D^{21}$ 1.6 (c 1.0, CHCl₃); IR (film) 3418, 3292, 3202, 2978, 1673, 1516, 1308, 1167, 1058, 545 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 6.84 (s, 1H), 5.86 (s, 1H), 5.79-5.70 (m, 1H), 4.81 (m, 1H), 4.52 (m, 1H), 4.24 (m, 2H), 3.86 (m, 2H), 3.70 (m, 2H), 2.74 (m, 2H), 1.44 (s, 9H), 1.34 (t, J = 6.8 Hz, 3H), 1.27 (m, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ 172.5 (m), 155.6 (m), 100.8 (m), 80.3 (s), 66.7–66.2 (m), 62.9 (m), 45.0 (m), 35.7 (m), 20.2 (s), 16.6 (m), 15.2 (m); ³¹P NMR (CDCl₃, 162 MHz) δ 38.44, 37.97; MS (ESI) m/z (%) 405.1 [M + Na]⁺; HRMS (ESI) Calcd for C₁₅H₃₂N₂O₇P 383.1942, found 383.1948.

Compound **3u**. **3u** was prepared from **9b** as the following procedure. **9b** (7.8 mg, 0.02 mmol) wa dissolved in 0.4 mL of chloroform, and 0.2 mL of TFA was added. After the reaction was stirred at room temperature for 1 h, the reaction was completed as indicated by TLC. The solution was concentrated to give 8 mg light yellow oil in quantitative yield: $[\alpha]_D^{23}$ 3.8 (*c* 0.5, MeOH); IR (film) 3350, 3187, 2983, 1677, 1421, 1204, 1057, 1028, 800, 722 cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ 5.00–4.96 (m, 1H), 4.22 (m, 2H), 3.94 (m, 1H), 3.82 (m, 2H), 3.66 (m, 2H), 2.88 (m, 1H), 2.67 (m, 1H), 1.30 (q, *J* = 6.8 Hz, 3H), 1.18 (t, *J* = 6.8 Hz, 6H); ¹³C NMR (CD₃OD, 100 MHz) δ 173.7 (m), 102.4 (m), 68.6–68.0 (m), 65.7 (m), 45.6–44.2 (m), 32.8–32.3 (m), 17.0 (m), 15.6 (m); ¹⁹F NMR (CD₃OD, 376 MHz) δ –77.33; ³¹P NMR (MeOD-4, 162 MHz) δ 34.55, 33.92; MS (ESI) *m/z* (%) 282.9 [M + H]⁺; HRMS (ESI) Calcd for C₁₀H₂₄A₂O₅P 283.1417, found 283.1412.

Procedure for Preparation of 4. Procedure A: 4 mL of 4 M aqueous HCl was added to 0.2 mmol phosphinate **2** at room temperature. The reaction was heated to reflux. After 15 h, it was cooled to room temperature. The solution was washed by DCM (2 mL \times 3). The aqueous phase was concentrated under a vacuum below the temperature of 40 °C. The residue was dissolved in 0.3 mL of EtOH, and then 20 mL of propylene oxide was added dropwise to the solution. White precipitate was formed. The mixture was stirred at room temperature overnight and then filtered to give white solid. Drying over the vacuum gave product **4a**, **4g**, **4o** or **4p**. Data for compound **4a** and **4g** were in accordance with reported literature.⁶

Procedure B: 2.5 mL of 4 M aqueous HCl was added to 0.5 mmol phosphinate 3 at room temperature. The reaction was heated to reflux for 1.5 h and then cooled to room temperature. The rest procedure was the same as Procedure A to give product 4c, 4f, 4h, 4i, 4j or 4k. Data for compound 4i and 4j were in accordance with reported literature.⁶

Compound 4a. Yield 80%, 17 mg. HPLC analysis of its dimethyl phosphonate derivate 2–7a: Chiralpak PC-2, *n*-hexane/2-propanol 50:50, $\lambda = 214$ nm, flow rate = 0.7 mL min⁻¹, retention time = 12.9 min, 10.8 min (89.8:10.2).

Compound 4c. Single isomer prepared from the major isomer of 3c. Yield 95%, 110 mg; white solid: mp 225–227 °C; $[\alpha]_D^{26}$ –96.0 (*c* 0.97, MeOH); IR (film) 3409, 3024, 2920, 1601, 1494, 1199, 963, 700 cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ 7.29 (d, *J* = 6.8 Hz, 2H), 7.24 (t, *J* = 6.8 Hz, 2H), 7.16 (d, *J* = 7.2 Hz, 1H), 3.75 (s, 2H), 3.38 (m, 1H), 2.91 (m, 1H), 2.68 (m, 1H); ¹³C NMR (CD₃OD, 100 MHz) δ 138.8 (s), 130.2 (s), 129.8 (s), 128.5 (s), 49.0 (d, *J* = 127.6 Hz), 36.6 (s), 28.7 (s); ³¹P NMR (CD₃OD, 121 MHz) δ 21.10, 20.55, 20.01 (1:1:1); MS (ESI) *m/z* (%) 232.1 [M + H]⁺; HRMS (ESI) Calcd for C₉H₁₅NO₂PS 232.0556, found 232.0563.

Compound 4f. Yield 97%, 73 mg; white solid: mp 229–231 °C; $[\alpha]_D^{27}$ –4.6 (*c* 1.0, H₂O); IR (film) 3414, 2966, 2388, 1639, 1608, 1536, 1458, 1170, 1044, 1020, 564, 452 cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ 7.03 (d, *J* = 520.4 Hz, 1H), 2.74 (m, 1H), 1.88 (m, 1H), 1.62 (m, 1H), 1.21 (m, 1H), 1.05 (d, *J* = 5.6 Hz, 3H), 0.89 (m, 3H); ¹³C NMR (CD₃OD, 100 MHz) δ 57.1 (d, *J* = 102.9 Hz), 35.4 (s), 26.6 (s), 16.2 (d, *J* = 5.9 Hz), 11.6 (s); ³¹P NMR (CD₃OD, 121 MHz) δ 16.18; MS (ESI) *m/z* (%) 150.1 [M – H]⁻; HRMS (MALDI) Calcd for C₅H₁₄NO₂PNa 174.0654, found 174.0654. HPLC analysis of its dimethylphosphonate derivative 7f: AD-H, *n*-hexane/2-propanol 50:50, λ = 214 nm, flow rate = 0.7 mL min⁻¹, retention time = 5.18 and 6.18 min (97.2:2.8).

Compound **4g.** Yield 33%, 10 mg. HPLC analysis of its dimethylphosphonate derivative **7g**: Chiralpak PC-2, *n*-hexane/2-propanol 50:50, $\lambda = 214$ nm, flow rate = 0.7 mL min⁻¹, retention time = 9.6 and 7.2 min (87.7:12.3).

Compound 4h. Yield 49%, 72 mg; white solid: mp 206–208 °C; $[α]_D^{28}$ –8.1 (c 0.83, H₂O); IR (film) 3448, 2940, 1773, 1706, 1542, 1400, 1173, 1044, 963, 894, 719 cm⁻¹; ¹H NMR (D₂O, 400 MHz) δ 7.70 (m, 4H), 6.92 (d, *J* = 532.8 Hz, 1H), 3.58 (m, 2H), 3.04 (m, 1H), 1.86 (m, 1H), 1.75–1.58 (m, 3H), 1.46 (m, 2H); ¹³C NMR (D₂O, 100 MHz) δ 170.7 (s); 134.7 (s); 131.3 (s); 123.3 (s); 50.4 (d, *J* = 91.2 Hz), 37.3 (s), 27.4 (s); 25.9 (s); 22.7 (d, *J* = 8.7 Hz); ³¹P NMR (D₂O, 121 MHz) δ 21.08; ESI (*m*/*z*) 295.0 [M – H]⁻; HRMS (MALDI) Calcd for C₁₃H₁₇N₂O₄PNa 319.0818, found 319.0815. HPLC analysis of its dimethylphosphonate derivative 7h: Chiralpak PC-2, *n*-hexane/ 2-propanol 50:50, λ = 214 nm, flow rate = 0.7 mL min⁻¹, retention time = 39.4 and 28.8 min (89.4:10.6).

Compound 4i. Yield 84%, 71 mg. Analysis of the 31 P NMR and 19 F NMR spectra of its Mosher's derivative 8i indicated a er value of 81.3:18.7.

Compound 4j. Yield 86%, 80 mg. HPLC analysis of its dimethylphosphonate derivative 7j: Chiralpak PC-2, *n*-hexane/2-propanol 50:50, $\lambda = 214$ nm, flow rate = 0.7 mL min⁻¹, retention time = 23.0 and 11.9 min (90.3:9.7).

Compound 4k. Yield 37%, 25 mg; white solid: mp 211 °C; $[\alpha]_D^{28}$ -6.7 (*c* 0.75, H₂O); IR (film) 3416, 2962, 2301, 1632, 1448, 1192, 1056, 966, 560 cm⁻¹; ¹H NMR (D₂O, 400 MHz) δ 6.98 (d, *J* = 537.6 Hz, 1H), 3.42 (m, 1H), 3.30 (t, *J* = 6.8 Hz, 2H), 2.19 (m, 1H), 2.07– 1.90 (m, 3H); ¹³C NMR (D₂O, 100 MHz) δ 57.5 (d, *J* = 91.2 Hz), 46.9 (d, *J* = 4.4 Hz), 24.0 (s), 23.8 (d, *J* = 7.3 Hz); ³¹P NMR (D₂O, 121 MHz) δ 19.69; ESI (*m*/*z*) 134.1 [M – H]⁻; HRMS (ESI) Calcd for C₄H₉NO₂P [M – H]⁻ 134.0373, found 134.0380. HPLC analysis of its dimethylphosphonate derivative 7k: Chiralpak PA-2, *n*-hexane/2propanol 50:50, λ = 214 nm, flow rate = 0.7 mL min⁻¹, retention time = 17.7 and 15.1 min (79.4:20.6).

Compound 40. Yield 60%, 26 mg; white solid: mp 228–230 °C; $[\alpha]_D^{26}$ –28.6 (*c* 1.4, H₂O/NaOH); IR (film) 2934, 1613, 1514, 1250, 1173, 1032, 817, 726, 568, 515 cm⁻¹; ¹H NMR (D₂O, 300 MHz) δ 6.98 (m, 2H), 6.66 (m, 2H), 6.47 (d, *J* = 508.8 Hz, 1H), 3.49 (s, 3H), 2.89–2.4 (m, 2H), 2.20 (m, 1H); ¹³C NMR (D₂O, 100 MHz) δ 157.5 (s); 130.9 (d, *J* = 14.6 Hz); 130.5 (s); 114.1 (s); 55.3 (s), 52.4 (d, *J* = 99.2 Hz), 34.3 (s); ESI (*m*/*z*) 213.9 [M – H]⁻; HRMS (MALDI) Calcd for C₉H₁₃NO₃P [M – H]⁻ 214.0638, found 214.0643. HPLC analysis of its dimethylphosphonate derivative 70: Chiralpak PC-2, *n*-hexane/2-propanol 50:50, λ = 214 nm, flow rate = 0.7 mL min⁻¹, retention time = 26.5 and 17.0 min (88.0:12.0).

Compound **4p**. Yield 40%, 11 mg; white solid: mp 230–232 °C; $[\alpha]_{\rm D}^{27}$ –2.44 (*c* 1.05, H₂O/NaOH); IR (film) 2962, 2359, 1640, 1548, 1468, 1177, 1042, 972, 548, 462 cm⁻¹; ¹H NMR (D₂O/NaOH, 300

MHz) δ 6.93 (d, J = 530.4 Hz, 1H), 2.75 (m, 1H), 2.10 (m, 1H), 0.96 (m, 6H); ¹³C NMR (D₂O/NaOH, 75 MHz) δ 56.4 (d, J = 91.6 Hz), 28.8 (s), 19.4 (d, J = 9.4 Hz) and 18.0 (d, J = 8.7 Hz); ³¹P NMR (D₂O/NaOH, 121 MHz) δ 19.58; ESI (m/z) 136.1 [M - H]⁻; HRMS (ESI) Calcd for C₄H₁₁NO₂P [M - H]⁻ 136.0533, found 136.0533. HPLC analysis of its dimethylphosphonate derivative 7**p**: Chiralpak PC-2, *n*-hexane/2-propanol 50:50, λ = 214 nm, flow rate = 0.7 mL min⁻¹, retention time = 8.9 and 7.5 min (99.6:0.4). Analysis of the NMR spectra of (*S*) and (*R*)-Mosher's derivatives of **5p** in which only one isomer was detected indicated similar dr value.

Compound (-)-4v. (-)-4v was prepared from (-)-9a according to the following procedure. (-)-9a (12 mg, 0.033 mmol) was dissolved in 0.66 mL of 4 M HCl, and the solution was heated to reflux for 2 h. The reaction was concentrated to give 6 mg of product in quantitative yield: $[\alpha]_D^{27}$ -0.39 (*c* 0.43, H₂O); IR (film) 3116, 3021, 1716, 1404, 1182, 1045, 668 cm⁻¹; ¹H NMR (D₂O, 400 MHz) δ 6.99 (d, *J* = 545.6 Hz, 1H), 3.47 (m, 1H), 2.91 (m 1H), 2.73 (m, 1H); ¹³C NMR (D₂O, 100 MHz) δ 173.6 (d, *J* = 11.7 Hz), 46.9 (d, *J* = 92.6 Hz), 30.5 (s); ³¹P NMR (D₂O, 162 MHz) δ 17.16; ESI (*m*/*z*) 152.0 [M - H]⁻; HRMS (ESI) Calcd for C₃H₇NO₄P [M - H]⁻ 152.0118, found 152.0125.

General Procedure for the Preparation of 10. To 0.55 mmol carboxylic compound in 3 mL of DCM, HOBt (90 mg, 0.6 mmol) and EDCI (130 mg, 0.6 mmol) were added at 0 °C. After 15 min, 0.5 mmol **3** in 2.5 mL of DCM was added. After 3 h, the reaction was warmed to room temperature and then stirred overnight. After completion of the reaction monitored by TLC, the reaction was quenched by 5 mL of sat. NaHCO₃ and then extracted with EtOAc (20 mL × 3). The combined organic phases were washed with 10 mL of brine, dried over anhydrous Na₂SO₄ and then purified by silica gel column chromatography with petroleum ether/ethyl acetate (2:3 to 1:2) to give **10**.

Compound **10a.** Yield 79%, 209 mg; sticky colorless oil: $[\alpha]_D^{28}$ -28.7 (*c* 1.3, CHCl₃); IR (film) 3278, 2976, 2932, 1681, 1519, 1498, 1366, 1170, 1058, 558 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.23– 7.13 (m, SH), 6.46 (d, *J* = 10.4 Hz, 1H), 5.0 (d, *J* = 6.0 Hz, 1H), 4.44 (m, 2H), 4.30 (q, *J* = 7.2 Hz, 1H), 4.04 (m, 2H), 3.75 (m, 2H), 3.54 (m, 2H), 3.10 (m, 1H), 2.95 (m, 1H), 1.95 (m, 1H), 1.63 (m, 1H), 1.33 (s, 9H), 1.16 (m, 9H), 1.01 (m, 1H), 0.89 (d, *J* = 6.4 Hz, 3H), 0.80 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (CDCl₃, 100 MHz) δ 171.0 (d, *J* = 5.1 Hz), 155.6 (s), 136.7 (s), 129.3 (s), 128.6 (s), 126.8 (s), 99.8 (d, *J* = 140.0 Hz), 80.2 (s), 66.2 (d, *J* = 10.2 Hz) and 64.9 (d, *J* = 8.0 Hz), 61.9 (d, *J* = 6.6 Hz), 55.7 (s), 49.9 (d, *J* = 94.1 Hz), 37.1 (s), 35.0 (s), 29.6 (s), 28.2 (s), 24.4 (s), 16.6 (m), 15.2 (m), 11.6 (s); ³¹P NMR (CDCl₃, 162 MHz) δ 38.43; ESI (*m*/z) 551.6 [M + Na]⁺; HRMS (MALDI) Calcd for C₂₆H₄₅N₂O₇PNa 551.2857, found 551.2837.

Compound **10b**. Yield >99%, 240 mg; sticky colorless oil: $[\alpha]_D^{28}$ -31.3 (*c* 1.25, CHCl₃); IR (film) 3278, 2974, 2933, 1716, 1673, 1521, 1366, 1209, 1173, 1060, 557 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 6.57–6.30 (m, 1H), 4.96 (d, *J* = 8.0 Hz, 1H), 4.69 (d, *J* = 9.2 Hz, 1H), 4.56–4.42 (m, 1H), 4.21 (m, 2H), 3.92–3.82 (m, 3H), 3.69 (m, 2H), 2.20 (m, 1H), 2.06 (m, 1H), 1.76 (m, 1H), 1.45 (s, 9H), 1.34–1.22 (m, 9H), 1.14 (m, 1H), 1.04–0.88 (m, 12H); ¹³C NMR (CDCl₃, 100 MHz) δ 171.5 (m), 155.8 (s), 100.0 (d, *J* = 140.0 Hz), 79.7 (s), 66.1 (m) and 64.7 (m), 61.8 (d, *J* = 5.1 Hz), 60.4 (s), 49.8 (d, *J* = 93.3 Hz), 35.0 (s), 29.9 (s), 28.1 (s), 24.3 (s), 19.3 (s), 17.7 (s), 16.5 (m), 15.1 (m), 11.5 (s); ³¹P NMR (CDCl₃, 162 MHz) δ 38.67, 38.56; ESI (*m*/z) 481.7 [M + H]⁺; HRMS (MALDI) Calcd for C₂₂H₄₅N₂O₇PNa 503.2857, found 503.2837.

Compound **10c**. Yield 81%, 208 mg; colorless oil: $[\alpha]_D^{-26}$ -40.4 (*c* 1.14, CHCl₃); IR (film) 3271, 2977, 2931, 1716, 1681, 1497, 1206, 1172, 1060, 1038, 751 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.22–7.09 (m, 5H), 6.92–6.77 (m, 1H), 4.93 (m, 1H), 4.81 (m, 1H), 4.67–4.60 (m, 1H), 4.16 (m, 2H), 3.85–3.45 (m, 5H), 3.20 (m, 1H), 2.83 (m, 1H), 1.92 (m, 1H), 1.38–1.31 (m, 9H), 1.27–1.17 (m, 9H), 0.72–0.57 (m, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ 171.1 (m), 155.7 (m), 136.8 (d, *J* = 11.9 Hz), 129.4 (s), 128.3 (s), 126.7 (s), 101.2 (d, *J* = 143.7 Hz), 79.7 (s), 66.6 (m), 62.9 (m) and 60.4 (m), 46.7 (d, *J* = 97.7 Hz), 34.4 (s), 30.5 (s), 28.3 (s), 19.2 (s), 17.3 (s) and 16.6 (s), 15.2 (m); ³¹P NMR (CDCl₃, 162 MHz) δ 38.90, 38.64, 38.49, 38.11;

ESI (m/z) 515.6 $[M + H]^+$; HRMS (MALDI) Calcd for $C_{25}H_{43}N_2O_7PNa$ 537.270, found 537.2708.

Compound 10d. Yield 85%, 244 mg; white solid: mp 66 °C; $[\alpha]_D^{30}$ -31.9 (c 1.0, CHCl₃); IR (film) 3256, 3064, 2977, 1721, 1670, 1536, 1450, 1246, 1208, 1059, 1036, 741 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) 7.75 (d, J = 7.2 Hz, 2H), 7.59 (d, J = 7.6 Hz, 2H), 7.38 (t, J = 7.6 Hz, 2H), 7.30 (t, J = 7.6 Hz, 2H), 7.15 (br, 1H), 5.75 (br, 1H), 4.78 (d, J = 9.2 Hz, 1H), 4.64 (m, 1H), 4.35 (m, 3H), 4.19 (m, 3H), 3.86 (m, 2H), 3.69 (m, 2H), 1.62 (m, 3H), 1.42 (d, J = 6.8 Hz, 3H), 1.26 (m, 9H), 0.91 (m, 6H); ¹³C NMR (CDCl₃, 126 MHz) δ 172.3 (s), 155.8 (s), 143.8 (s), 141.3 (s), 127.7 (s), 127.1 (s), 125.1 (s), 120.0 (s), 100.4 (d, J = 137.1 Hz), 67.0 (s), 66.4 (d, J = 8.7 Hz) and 64.9 (d, J = 8.8 Hz), 62.5 (d, J = 7.3 Hz), 50.5 (s), 47.1 (s), 44.1 (d, J = 94.8 Hz), 37.4 (s), 24.5 (d, J = 12.4 Hz), 23.5 (s), 21.1 (s), 19.4 (s), 16.7 (d, J = 5.1 Hz), 15.3 (d, J = 3.6 Hz); ³¹P NMR (CDCl₃, 162 MHz) δ 39.51, 39.22, 38.80, 38.46; ESI (m/z) 597.5 $[M + Na]^+$; HRMS (MALDI) Calcd for C₃₀H₄₃N₂O₇PNa 597.270, found 597 2670

Compound **10e**. Yield 93%, 287 mg; colorless oil: $[\alpha]_D^{30} - 22.9$ (c 1.0, CHCl₃); IR (film) 3264, 2977, 2934, 1713, 1525, 1397, 1056, 721 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.80 (m, 2H), 7.67 (m, 2H), 7.35–7.30 (m, 5H), 6.92 (br, 1H), 5.89 (br, 1H), 5.11 (s, 2H), 4.76 (d, *J* = 8.8 Hz, 1H), 4.52 (m, 1H), 4.17 (m, 2H), 3.92 (m, 2H), 3.84 (m, 2H), 3.70–3.63 (m, 4H), 1.94 (m, 1H), 1.76–1.58 (m, 3H), 1.40 (m, 2H), 1.29–1.21 (m, 9H); ¹³C NMR (CDCl₃, 100 MHz) δ 169.0 (s), 168.5 (s), 156.5 (s), 136.3 (s), 133.9 (s), 132.0 (s), 128.5 (s), 128.2 (s), 128.1 (s), 123.2 (s), 100.5 (d, *J* = 140.0 Hz), 67.0 (s), 66.3 (d, *J* = 9.5 Hz) and 65.3 (d, *J* = 8.8 Hz), 62.6 (d, *J* = 7.3 Hz), 45.7 (d, *J* = 95.6 Hz), 44.5 (s), 37.3 (s), 28.0 (s), 27.9 (s), 22.8 (d, *J* = 11.6 Hz), 16.7 (m), 15.2 (m); ³¹P NMR (CDCl₃, 162 MHz) δ 38.64, 38.48, 38.38; ESI (*m*/*z*) 618.6 [M + H]⁺; HRMS (MALDI) Calcd for C₃₀H₄₀N₃O₉PNa 640.2394, found 640.2387.

Compound 10f. Yield 76%, 237 mg; white solid: mp 78-85 °C; $[\alpha]_{D}^{30}$ –16.4 (c 1.29, CHCl₃); IR (film) 3280, 2975, 2932, 1713, 1648, 1535, 1212, 1059, 755 cm $^{-1};$ $^1\rm H$ NMR (CDCl_3, 400 MHz) δ 7.65 – 7.41 (m, 1H), 7.24 (m, 5H), 6.88 (m, 1H), 5.91 (m, 1H), 4.74 (m, 1H), 4.59 (m, 2H), 4.44 (m, 1H), 4.21 (m, 2H), 3.88 (m, 2H), 3.71 (m, 2H), 3.07 (d, J = 5.6 Hz, 2H), 2.05 (m, 2H), 1.87 (m, 1H), 1.39-1.36 (m, 9H), 1.30–1.21 (m, 9H), 1.18–0.83 (m, 13H); ¹³C NMR (CDCl₃, 100 MHz) δ 171.8 (m), 171.3 (m), 155.7 (s), 137.0 (s), 129.2 (s), 128.4 (s), 126.6 (s), 100.5 (d, J = 137.1 Hz), 79.5 (s), 66.2 (d, J = 8.7 Hz), 64.9 (m) and 62.0 (m), 58.3 (s), 55.9 (s), 50.2 (d, J =89.7 Hz), 37.4 (s), 35.1 (s), 30.9 (s), 28.2 (s), 24.3 (m), 19.3 (s), 17.9 (s), 16.5 (m), 15.2 (m), 11.8 (m); $^{31}\mathrm{P}$ NMR (CDCl₃, 162 MHz) δ 38.75; ESI (m/z) 650.8 $[M + Na]^+$; HRMS (ESI) Calcd for C₃₁H₅₄N₃O₈PNa 650.3541, found 650.3521. Elemental analysis (%) calcd for C₃₁H₅₄N₃O₈P: C 59.31; H 8.67; N 6.69. Found: C 59.18; H 8.55; N 6.49.

Compound **10g.** Yield 78%, 253 mg; white solid: mp 78 °C; $[\alpha]_D^{30}$ –18.7 (*c* 1.0, CHCl₃); IR (film) 3268, 2975, 2931, 1716, 1648, 1537, 1211, 1058, 754 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.63–7.41 (m, 1H), 7.23 (m, 5H), 6.90 (m, 1H), 5.62 (m, 1H), 4.82 (m, 1H), 4.63 (m, 1H), 4.54–4.40 (m, 2H), 4.21 (m, 2H), 3.87 (m, 2H), 3.70 (m, 2H), 3.05 (m, 2H), 2.13 (m, 1H), 1.61 (m, 2H), 1.38 (s, 9H), 1.32–1.24 (m, 9H), 0.90–0.76 (m, 13H); ¹³C NMR (CDCl₃, 100 MHz) δ 171.5 (m), 170.7 (m), 155.3 (m), 136.8 (s), 129.3 (s), 128.5 (s), 126.7 (s), 100.3 (d, *J* = 137.1 Hz), 79.7 (s), 66.2 (d, *J* = 8.0 Hz), 64.7 (m) and 62.4 (m), 58.1 (s), 55.9 (s), 44.0 (d, *J* = 105.0 Hz), 37.4 (m), 31.0 (m), 28.2 (s), 24.4 (m), 23.5 (s), 21.0 (s), 19.3 (s) and 17.7 (s), 16.6 (m), 15.2 (m); ³¹P NMR (CDCl₃, 162 MHz) δ 39.65, 39.31, 38.90, 38.62; ESI (*m*/*z*) 650.8 [M + Na]⁺; HRMS (MALDI) Calcd for C₃₁H₄₄N₃O₈PNa 650.3541, found 650.3522.

Compound 10h. Yield 35%, 116 mg; white solid: mp 99 °C; $[\alpha]_D^{27}$ -29.8 (*c* 1.0, CHCl₃); IR (film) 3266, 2975, 1714, 1647, 1542, 1214, 1170, 1058, 668 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.22–7.10 (m, 10H), 6.68 (br, 1H), 6.35 (br, 1H), 5.25–4.90 (m, 1H), 4.75 (m, 1H), 4.59 (m, 1H), 4.27 (m, 1H), 4.18 (m, 2H), 4.01 (m, 1H), 3.80–3.64 (m, 3H), 3.49 (m, 1H), 3.18 (m, 1H), 3.07–2.78 (m, 3H), 1.87 (m, 1H), 1.31 (s, 9H), 1.27–1.17 (m, 9H), 0.72–0.52 (m, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ 171.3 (m), 170.4 (m), 155.4 (m), 136.9 (m), 136.8 (s), 136.7 (s), 129.3 (s), 128.7 (s), 128.4 (s), 126.9 (m), 126.7 (s), 100.6 (d, J = 138.5 Hz), 80.2 (m), 66.5 (m), 65.2 (m) and 62.8 (m), 58.4 (m), 56.1 (m), 47.0 (d, J = 94.0 Hz), 38.6 (m), 34.7 (m), 30.6 (m), 28.3 (s), 19.0 (m) and 17.5 (m), 16.6 (m), 15.3 (m); ³¹P NMR (CDCl₃, 162 MHz) δ 38.33, 38.03, 37.74; ESI (*m*/*z*) 662.8 [M + H]⁺; HRMS (MALDI) Calcd for C₃₄H₅₂N₃O₈PNa 684.3384, found 684.3392.

Compound 10i. Yield 67%, 206 mg; white solid: mp 90 °C; $[\alpha]_D^{27}$ -5.5 (*c* 1.33, CHCl₃); IR (film) 3279, 2976, 2931, 1714, 1649, 1535, 1391, 1366, 1211, 1173, 1058, 756 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.44 (m, 1H), 7.15 (m, 5H), 6.74 (m, 1H), 5.93 (m, 1H), 4.70–4.31 (m, 4H), 4.21 (m, 2H), 3.82–3.42 (m, 4H), 2.99 (m, 2H), 2.20 (m, 1H), 2.02 (m, 1H), 1.29 (s, 9H), 1.24–1.12 (m, 9H), 0.96– 0.70 (m, 12H); ¹³C NMR (CDCl₃, 100 MHz) δ 171.8 (m), 171.4 (m), 155.7 (m), 137.2 (m), 129.2 (s), 128.4 (s), 126.6 (s), 100.7 (m), 79.5 (m), 66.9 (m), 66.2 (m), 62.7 (m), 58.3 (m), 56.0 (m), 50.0 (m), 37.5 (m), 31.2 (m), 130.6 (m), 28.2 (s), 20.8 (m) and 19.4 (m), 18.4 (m) and 17.7 (m), 16.6 (m), 15.2 (m); ³¹P NMR (CDCl₃, 162 MHz) δ 38.90, 38.70, 38.64; ESI (*m*/*z*) 614.8 [M + H]⁺; HRMS (MALDI) Calcd for C₃₀H₅₂N₃O₈PNa 636.3384, found 636.3399.

Compound **10***j*. Yield 98%, 252 mg; colorless oil: $[\alpha]_D^{26}$ –21.1 (*c* 1.0, CHCl₃); IR (film) 3271, 2977, 2931, 1714, 1668, 1522, 1498, 1366, 1210, 1171, 1058, 557 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 7.18 (m, 5H), 6.62 (br, 1H), 5.22 (br, 1H), 4.63–4.48 (m, 1H), 4.37 (m, 2H), 4.10 (m, 2H), 3.73 (m, 2H), 3.56 (m, 2H), 3.15–2.89 (m, 2H), 2.23 (m, 1H), 1.32–1.30 (m, 9H), 1.25–1.12 (m, 9H), 0.93–0.75 (m, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ 171.4 (m), 155.6 (m), 136.8 (s), 129.2 (m), 128.5 (m), 126.8 (m), 100.4 (m), 80.1 (m), 66.3 (m), 64.8 (m), 62.5 (m) and 62.0 (m), 55.8 (m), 49.6 (m), 37.2 (m), 28.2 (m), 20.6 (m), 16.6 (m), 15.2 (m); ³¹P NMR (CDCl₃, 162 MHz) δ 38.61, 38.31, 38.25; ESI (*m*/*z*) 515.6 [M + H]⁺; HRMS (ESI) Calcd for C₂₅H₄₃N₂O₇PNa 537.270, found 537.2718.

Compound **10k.** Yield 82%, 217 mg; colorless oil: $[\alpha]_D^{26}$ -31.0 (*c* 1.0, CHCl₃); IR (film) 3258, 2977, 1715, 1668, 1523, 1498, 1366, 1209, 1366, 1209, 1172, 1058, 563 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 7.27–7.18 (m, SH), 6.41 (br, 1H), 4.90 (br, 1H), 4.67 (d, *J* = 9.5 Hz, 1H), 4.59 (q, *J* = 9.5 Hz, 1H), 4.37 (d, *J* = 6.5 Hz, 1H), 4.11 (m, 2H), 3.82 (m, 2H), 3.63 (m, 2H), 3.13–3.09 (m, 1H), 3.02 (m, 1H), 1.60 (m, 1H), 1.49 (m, 2H), 1.37 (s, 9H), 1.28–1.19 (m, 9H), 0.90 (d, *J* = 6.0 Hz, 3H), 0.87 (d, *J* = 6.5 Hz, 3H); ¹³C NMR (CDCl₃, 126 MHz) δ 170.8 (d, *J* = 3.8 Hz), 155.4 (s), 136.5 (s), 129.4 (s), 128.6 (s), 126.9 (s), 100.6 (d, *J* = 141.5 Hz), 80.2 (s), 66.2 (d, *J* = 9.6 Hz), 64.8 (d, *J* = 7.7 Hz), 62.2 (d, *J* = 6.7 Hz), 55.6 (s), 44.0 (d, *J* = 95.5 Hz), 37.2 (s), 28.2 (s), 24.2 (d, *J* = 11.5 Hz), 23.5 (s), 20.9 (s), 16.7 (d, *J* = 4.8 Hz), 15.2 (d, *J* = 5.8 Hz); ³¹P NMR (CDCl₃, 162 MHz) δ 39.14, 39.02; ESI (*m*/z) 529.8 [M + H]⁺; HRMS (ESI) Calcd for C₂₆H₄₅N₂O₇PNa 551.2857, found 551.2838.

Compound **10***I*. Yield 44%, 139 mg; white solid: mp 133–139 °C; $[\alpha]_D^{27}$ –21.5 (*c* 1.0, CHCl₃); IR (film) 3285, 2977, 2930, 1660, 1536, 1168, 1058, 1032, 699 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 7.33–7.19 (m, 10H), 6.82–6.59 (m, 2H), 4.94 (m, 1H), 4.73–4.66 (m, 1H), 4.49 (m, 1H), 4.42 (d, *J* = 5.5 Hz, 2H), 4.33 (m, 1H), 4.14 (m, 2H), 3.82 (m, 2H), 3.64 (m, 2H), 3.18–3.14 (m, 1H), 2.98 (m, 1H), 2.27 (m, 3H), 1.92 (s, 1H), 1.36–1.34 (m, 9H), 1.28 (m, 3H), 1.25–1.21 (m, 6H); ¹³C NMR (CDCl₃, 126 MHz) δ 172.0 (s), 171.8 (m), 155.5 (m), 138.5 (s), 136.4 (s), 129.3 (s), 128.7 (s), 128.6 (s), 127.8 (s), 127.3 (s), 127.0 (s), 100.2 (d, *J* = 142.5 Hz), 80.3 (s), 66.4 (m), 65.5 (m), 62.5 (m), 55.9 (s), 45.8 (d, *J* = 96.5 Hz), 43.5 (s), 37.5 (s), 32.8 (d, *J* = 12.5 Hz), 28.2 (s), 25.6 (d, *J* = 3.9 Hz), 16.6 (m), 15.2 (m); ³¹P NMR (CDCl₃, 162 MHz) δ 37.70, 37.66, 37.41; ESI (*m*/*z*) 634.7 [M + H]⁺; HRMS (ESI) Calcd for C₃₂H₄₈N₃O₈PNa 656.3071, found 656.3070.

Compound **10m**. Yield 78%, 221 mg; white solid: mp 68–70 °C; $[\alpha]_{D}^{26}$ –26.9 (*c* 1.0, CHCl₃); IR (film) 3293, 2976, 2932, 1696, 1511, 1210, 1168, 1058, 742, 558 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 8.95 (br, 1H), 7.63 (d, *J* = 7.6 Hz, 1H), 7.37 (d, *J* = 8.0 Hz, 1H), 7.18 (t, *J* = 6.8 Hz, 1H), 7.12–7.08 (m, 2H), 6.50 (dd, *J*₁ = 10.4 Hz, *J*₂ = 1.6 Hz, 1H), 5.07 (d, *J* = 7.2 Hz, 1H), 4.57–4.46 (m, 3H), 4.17–4.02 (m, 2H), 3.80 (m, 2H), 3.60 (m, 2H), 3.26 (m, 2H), 1.97 (m, 1H), 1.64 (m, 1H), 1.40 (s, 9H), 1.22 (m, 9H), 1.02 (m, 1H), 0.91 (d, *J* = 6.8 Hz, 3H), 0.84 (t, J = 7.2 Hz, 3H); ¹³C NMR (CDCl₃, 100 MHz) δ 171.7 (d, J = 5.1 Hz), 155.8 (s), 136.4 (s), 127.4 (s), 123.5 (s), 122.0 (s), 119.5 (s), 118.6 (s), 111.4 (s), 110.0 (s), 99.8 (d, J = 140.7 Hz), 80.3 (s), 66.4 (d, J = 9.5 Hz), 65.0 (d, J = 8.8 Hz), 62.1 (d, J = 7.3 Hz), 55.4 (s), 49.8 (d, J = 94.0 Hz), 35.0 (s), 28.2 (s), 24.5 (d, J = 2.2 Hz), 16.6 (d, J = 5.1 Hz), 16.5 (d, J = 11.0 Hz), 15.3 (d, J = 4.4 Hz), 11.6 (s); ³¹P NMR (CDCl₃, 162 MHz) δ 39.20, 38.84, 38.75; ESI (m/z) 568.7 [M + H]⁺; HRMS (ESI) Calcd for C₂₈H₄₆N₃O₇PNa 590.2966, found 590.2953.

NMR data for 6p and (–)-6p. (*R*)-Mosher's Derivative of 5p (6p). ¹H NMR (CDCl₃, 400 MHz) δ 7.55 (m, 2H), 7.40 (m, 3H), 7.17 (d, J = 10.4 Hz, 1H), 4.35 (m, 1H), 4.11 (m, 2H), 4.01 (m, 2H), 3.38 (s, 3H), 2.31 (m, 1H), 1.30–1.20 (m, 6H), 1.06 (d, J = 6.4 Hz, 6H); ¹⁹F NMR (CDCl₃, 282 MHz) δ –69.42; ³¹P NMR (CDCl₃, 121 MHz) δ 24.56; ESI (m/z) 426.3 [M + H]⁺.

(*S*)-Mosher's Derivative of **5p** ((-)-**6p**). ¹H NMR (CDCl₃, 400 MHz) δ 7.57 (m, 2H), 7.40 (m, 3H), 6.84 (d, *J* = 9.6 Hz, 1H), 4.35 (m, 1H), 4.18-4.10 (m, 4H), 3.52 (s, 3H), 2.25 (m, 1H), 1.33 (dt, *J*₁ = 2.8 Hz, *J*₂ = 7.2 Hz, 6H), 0.93 (dd, *J*₁ = 6.8 Hz, *J*₂ = 21.2 Hz, 6H); ¹⁹F NMR (CDCl₃, 282 MHz) δ -69.12; ³¹P NMR (CDCl₃, 121 MHz) δ 24.47; ESI (*m*/*z*) 426.3 [M + H]⁺.

NMR Data for Mosher'S Derivative of the Major Isomer of **3m**. (*R*)-Mosher's Derivative of the Major Isomer of **3m**. ¹H NMR (CDCl₃, 400 MHz) δ 7.58 (m, 2H), 7.52 (m, 1H), 7.40 (m, 3H), 7.36 (m, 2H), 7.34–7.28 (m, 2H), 5.31 (s, 1H), 4.66 (d, *J* = 11.2 Hz, 1H) and 4.51 (d, *J* = 11.2 Hz, 1H), 4.54 (td, *J*₁ = 10.4 Hz, *J*₂ = 1.6 Hz, 1H), 4.48 (d, *J* = 10.0 Hz, 1H), 4.36 (m, 1H), 4.13–3.95 (m, 2H), 3.84–3.44 (m, 4H), 3.89 (d, *J* = 1.2 Hz, 3H), 1.26 (dd, *J*₁ = 1.6 Hz, *J*₂ = 6.4 Hz, 3H), 1.16 (q, *J* = 7.2 Hz, 6H), 1.11 (t, *J* = 7.2 Hz, 3H); ¹⁹F NMR (CDCl₃, 376 MHz) δ –69.13; ³¹P NMR (CDCl₃, 162 MHz) δ 36.23.

(S)-Mosher's Derivative of the Major Isomer of **3m**. ¹H NMR (CDCl₃, 400 MHz) δ 7.60 (m, 2H), 7.40 (m, 3H), 7.31–7.24 (m, SH), 5.30 (s, 1H), 4.61 (d, *J* = 10.4 Hz, 1H), 4.55 (td, *J*₁ = 10.4 Hz, *J*₂ = 1.6 Hz, 1H), 4.55 (d, *J* = 11.2 Hz, 1H) and 4.46 (d, *J* = 11.2 Hz, 1H), 4.32 (m, 1H), 4.21–4.03 (m, 2H), 3.92–3.49 (m, 4H), 1.21 (t, *J* = 7.2 Hz, 3H), 1.20 (q, *J* = 7.1 Hz, 6H), 1.08 (dd, *J*₁ = 1.6 Hz, *J*₂ = 6.4 Hz, 3H); ¹⁹F NMR (CDCl₃, 376 MHz) δ –68.75; ³¹P NMR (CDCl₃, 162 MHz) δ 35.98.

ASSOCIATED CONTENT

S Supporting Information

NMR spectra of new compounds 1-4, 9, 10, 6p, (-)-6p, Mosher's derivatives of the major isomer of 3m; HPLC data for 6 and 7. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

*E-mail: yuancy@mail.sioc.ac.cn.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

The project was supported by the National Science Foundation of China (Grant No. 21072212). We thank the National Center for Drug Screening for biological activities study.

REFERENCES

(1) Selective reviews for the preparation of amino phosphonic acids: (a) Kukhar, V. P.; Soloshonok, V. A.; Solodenko, V. A. *Phosphorus Sulfur Relat. Elem.* **1994**, 92 (1–4), 239–264. (b) Ma, J. *Chem. Soc. Rev.* **2006**, 35, 630–636. (c) Mario, O.; Haydee, R.; Carlos, C. *Tetrahedron* **2009**, 65, 17–49. (d) Albrecht, L.; Albrecht, A.; Krawczyk, H.; Jørgensen, K. A. *Chem—Eur. J.* **2010**, *16*, 28–28. (e) Lefebvre, I. M.; Evans, S. A. J. Org. Chem. **1997**, *62*, 7532–7533.

(2) Selective reviews for biological studies of phosphonic acids: (a) Orsini, F.; Sello, G.; Sisti, M. Curr. Med. Chem. 2010, 17 (3), 264–

289. (b) Galezowska, J.; Gumienna-Kontecka, E. *Coord. Chem. Rev.* 2012, 256, 105–124.

(3) (a) Gerald, L. R.; Arno, L. G.; George, L. K. J. Am. Chem. Soc. 1971, 93, 5542–5551. (b) Marion, C.; Elizabeth, A. K.; Kathy, L. K.; Karen, M. A.; James, F. K. Bioorg. Med. Chem. Lett. 1996, 6 (9), 999– 1002.

(4) Selective reviews for biological studies of phosphinic acids, see:
(a) Berlicki, L.; Kafarski, P. *Curr. Org. Chem.* 2005, 9, 1829–1850.
(b) Yiotakis, A.; Georgiadis, D.; Matziari, M.; Makaritis, A.; Dive, V. *Curr. Org. Chem.* 2004, 8, 1135–1158. (c) Collinsova, M.; Jiracek, J. *Curr. Med. Chem.* 2000, 7 (6), 629–647.

(5) Yao, Q.; Yuan, C. J. Org. Chem. 2012, 77, 10985–10990 and references cited therein.

(6) Baylis, E. K.; Campbell, C. D.; Dingwall, J. G. J. Chem. Soc., Perkin Trans. 1 1989, 2845–2853.

(7) To be specific, the following analogues were synthesized asymmetrically. (a) Analogues of Ala and Phe: Patrick, P. M.; Brian, T. J. Chem. Soc., Perkin Trans. 1 1984, 1319–1329. (b) Analogues of Ala, Phe, Val, and Leu: Hamilton, R.; Walker, B.; Walker, B. J. Tetrahedron Lett. 1995, 36 (25), 4451–4454. (c) Analogue of Met: Kirill, V. A.; Yurii, N. Z.; Nikolai, G. F.; Elena, N. K.; Radii, M. K. Mendeleev Commun. 2003, 13 (3), 127–128.

(8) Zhang, D. H.; Yuan, C. Y. Chem.—Eur. J. 2008, 14, 6049–6052.
(9) (a) David, F. A.; Reddy, G. V.; Liu, H. J. Am. Chem. Soc. 1995,

117, 3651–3653. (b) Liu, G.; Cogan, D. A.; Owens, T. D.; Tang, T. P.; Ellman, J. A. J. Org. Chem. **1999**, 64, 1278–1284.

 $\left(10\right)$ See Experimental Section and Supporting Information for detailed NMR data.

(11) Galaktionov, K.; Beach, D. Cell 1991, 67 (6), 1181-1194.

(12) Kells, K. W.; Chong, J. M. Org. Lett. 2003, 5 (22), 4215-4218.

(13) Asada, M.; Obitsu, T.; Kinoshita, A.; Nagase, T.; Yoshida, T.; Yamaura, Y.; Takizawa, H.; Yoshikawa, K.; Sato, K.; Narita, M.; Nakai,

H.; Toda, M.; Tobe, Y. *Bioorg. Med. Chem.* **2010**, *18* (9), 3212–3223. (14) Tang, T. P.; Volkman, S. K.; Ellman, J. A. J. Org. Chem. **2001**, *66*, 8772–8778.